<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Genomics</journal-id><journal-title-group><journal-title>BMC Genomics</journal-title></journal-title-group><issn pub-type="epub">1471-2164</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2164-10-613</article-id><article-id pub-id-type="pmid">20015385</article-id><article-id pub-id-type="doi">10.1186/1471-2164-10-613</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research article</subject></subj-group></article-categories><title-group><article-title>Increased epithelial stem cell traits in advanced endometrial endometrioid carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Chang</surname><given-names>Shing-Jyh</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>justine3@ms8.hinet.net</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Wang</surname><given-names>Tao-Yeuan</given-names></name><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref><email>tywang@ms2.mmh.org.tw</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Tsai</surname><given-names>Chan-Yen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>chanyentw@yahoo.com.tw</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Hu</surname><given-names>Tzu-Fang</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yvonne74129@hotmail.com</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Chang</surname><given-names>Margaret Dah-Tsyr</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>lscmdt@life.nthu.edu.tw</email></contrib><contrib contrib-type="author" corresp="yes" id="A6"><name><surname>Wang</surname><given-names>Hsei-Wei</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I7">7</xref><email>hwwang@ym.edu.tw</email></contrib></contrib-group><aff id="I1"><label>1</label>Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan</aff><aff id="I2"><label>2</label>VGH-YM Genome Research Center, National Yang-Ming University, Taipei, Taiwan</aff><aff id="I3"><label>3</label>Department of Obstetrics and Gynecology, Hsinchu Mackay Memorial Hospital, Hsinchu, Taiwan</aff><aff id="I4"><label>4</label>Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu, Taiwan</aff><aff id="I5"><label>5</label>Department of Pathology, Mackay Memorial Hospital, Taipei, Taiwan</aff><aff id="I6"><label>6</label>Mackay Medicine, Nursing and Management College, Taipei, Taiwan</aff><aff id="I7"><label>7</label>Department of Education and Research, Taipei City Hospital, Taipei, Taiwan</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2009</year></pub-date><volume>10</volume><fpage>613</fpage><lpage>613</lpage><history><date date-type="received"><day>4</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>16</day><month>12</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2009 Chang et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Chang et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2164/10/613"/><abstract><sec><title>Background</title><p>It has been recognized cancer cells acquire characters reminiscent of those of normal stem cells, and the degree of stem cell gene expression correlates with patient prognosis. Lgr5(+) or CD133(+) epithelial stem cells (EpiSCs) have recently been identified and these cells are susceptible to neoplastic transformation. It is unclear, however, whether genes enriched in EpiSCs also contribute in tumor malignancy. Endometrial endometrioid carcinoma (EEC) is a dominant type of the endometrial cancers and is still among the most common female cancers. Clinically endometrial carcinoma is classified into 4 FIGO stages by the degree of tumor invasion and metastasis, and the survival rate is low in patients with higher stages of tumors. Identifying genes shared between advanced tumors and stem cells will not only unmask the mechanisms of tumor malignancy but also provide novel therapeutic targets.</p></sec><sec><title>Results</title><p>To identify EpiSC genes in late (stages III-IV) EECs, a molecular signature distinguishing early (stages I-II) and late EECs was first identified to delineate late EECs at the genomics level. ERBB2 and CCR1 were genes activated in late EECs, while APBA2 (MINT2) and CDK inhibitor p16 tumor suppressors in early EECs. MAPK pathway was significantly up in late EECs, indicating drugs targeting this canonical pathway might be useful for treating advanced EECs. A six-gene mini-signature was further identified to differentiate early from advanced EECs in both the training and testing datasets. Advanced, invasive EECs possessed a clear EpiSC gene expression pattern, explaining partly why these tumors are more malignant.</p></sec><sec><title>Conclusions</title><p>Our work provides new insights into the pathogenesis of EECs and reveals a previously unknown link between adult stem cells and the histopathological traits of EECs. Shared EpiSC genes in late EECs may contribute to the stem cell-like phenotypes shown by advanced tumors and hold the potential of being candidate therapeutic targets and novel prognosis biomarkers.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Tumor development, progression, and prognosis remain at the front position of medical research. Two hypotheses of the origin of cancer have existed for many decades. One hypothesis postulates that adult stem or precursor cell is the cell of origin for cancer, whereas the other declares a somatic cell can be mutated and then be dedifferentiated or be reprogrammed to regain properties associated with both cancer cells and stem cells [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. The discovery of a subpopulation of tumor stem cells (TSCs) in leukemia and solid cancers has strengthened the stem cell hypothesis [<xref ref-type="bibr" rid="B4">4</xref>]. Glioblastomas also possess characters and gene expression patterns of local neural stem cells (NSCs) [<xref ref-type="bibr" rid="B5">5</xref>], and artificially introducing cancer-associated mutations into stem or lineage-restricted precursor cells can indeed turn them into cancer initiating cells and all mice received mutations developed medulloblastomas [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Another example that the adult stem cell represents the cell of origin of cancer has recently been made in chronic myeloid leukemia (CML): by restricting BCR-ABLp210 expression to mouse Sca1(+) hematopoietic stem cells, it is sufficient to induce CML formation that recapitulates the human disease [<xref ref-type="bibr" rid="B8">8</xref>]. These evidences support the idea that mutations of stem cells may initiate the carcinogenic process of certain, although not necessary all, tumors.</p><p>On the other hand, the importance of somatic or tumor cell mutation and dedifferentiation has not been excluded completely. It has been recognized that during malignant transformation, cancer cells acquire genetic mutations that override the normal mechanisms controlling cellular proliferation. Human tumor cells can be created from healthy somatic cells with defined genetic elements [<xref ref-type="bibr" rid="B9">9</xref>]. Even though cancers were originated from mutated stem cells, newly acquired mutations in tumors still contribute in cell malignancy and therapy resistance. It has been recognized that cancer cells acquire characters reminiscent of those of normal stem cells. Clinically cancer cells with poor differentiated pathological grading usually have worse therapy response than those with well differentiated morphology. The degree of embryonic gene re-expression correlates with pivotal tumor features and patient prognosis [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. It is known that colon cancers adopt a broad program encompassing embryonic colon development [<xref ref-type="bibr" rid="B12">12</xref>]. In poorly differentiated breast cancer, gliomas and bladder carcinoma, an embryonic stem cell (ESC)-like gene expression signature is exhibited and the degree of ESC program recapitulation correlates with tumor stages and patient survival [<xref ref-type="bibr" rid="B13">13</xref>]. Recent studies demonstrated that Snail, a potent oncogene which can induce epithelial-mesenchymal transition (EMT), contributes to the acquisition of stem cell traits in breast cancer cells [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Pre-existing cancerous lesions may become more malignant by the accumulation of new oncogenic mutations (such as Snail) that can induce cell dedifferentiation. Identifying genes shared between transformed cells, especially the more malignant ones, and stem cells will help to unmask the pathogenesis of tumors, as well as provide us with novel therapeutic targets and prognosis biomarkers.</p><p>Endometrial carcinoma of the female genital tract can be divided into two forms: endometrial endometrioid carcinoma (EEC; Type I) which account for 70-80% of cases and are estrogen-related; whereas the Type II tumors (papillary serous or clear cell tumors) account for 20% of cases unrelated to estrogen stimulation [<xref ref-type="bibr" rid="B16">16</xref>]. Clinically endometrial carcinoma is classified into 4 FIGO stages by the degree of invasion and metastasis: stage I tumors are limit to the uterine body and stage II tumors extend to the uterine cervix. Both stages are considered as less invasive, although stage IIB cases are characterized by a less favorable prognosis. In contrast, tumors of stages III-IV are invasive: for stage III there is regional tumor spread and for stage IV there is bulky pelvic disease or distant spread [<xref ref-type="bibr" rid="B17">17</xref>]. Approximately 72% of endometrial carcinomas are stage I, 12% are stage II, 13% are stage III, and 3% are stage IV [<xref ref-type="bibr" rid="B17">17</xref>]. The survival rate is also low in patients with higher stages of tumors: 80-90% in stage I, 70-80% in stage II, 40-60% in stage III, and 20% in stage IV [<xref ref-type="bibr" rid="B17">17</xref>]. Identifying genes abundant in late EECs can not only unmask the mechanisms of tumor malignancy but also provide us with novel therapeutic targets. Recently Lgr5- or CD133-positive crypt stem cells of the intestinal track were identified and these cells were proven to be one of the original cells of intestinal cancer [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. OLFM4 is also a new, robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells [<xref ref-type="bibr" rid="B20">20</xref>]. Disruption of beta-catenin in cells positive for CD133 resulted in a gross disruption of crypt architecture and a disproportionate expansion of CD133(+) cells at the crypt base [<xref ref-type="bibr" rid="B19">19</xref>]. It is unclear, however, whether genes high expressed in epithelial stem cells (EpiSCs) also contribute in tumor invasiveness, malignancy and therapy resistance. A broad description of stem cell traits reminiscent in EECs is therefore crucial.</p><p>In this study we dealt with the molecular bases of endometrial cancer and assessed the expression of epithelial precursor genes in advanced EEC. To examine the shared genes between EpiSC and late EECs, we first need to unmask the gene compositions in different stages of EECs. For this purpose we applied gene expression microarray and machine learning algorithms to filtrate genes differentially expressed in early (stages I-II) and late (stages III-IV) EECs. After obtaining genes unique in EECs of different stages, we then related transcriptional programs in EpiSCs and late EECs. This approach helped to discover a total of 217 probe sets differentiating EECs of different stages, and, moreover, showed late EECs possess a clear EpiSC gene expression pattern, partly explaining why these tumors are more malignant and fatal.</p></sec><sec><title>Results</title><sec><title>Molecular signatures of early and late stage EECs</title><p>To identify epithelial stem cell genes in late EECs, we first delineated early (FIGO stages I and II) and late (FIGO stages III and IV) EECs at the genomics level. We explored genes differentially expressed between early and late EEC tissues using the Affymetrix U133 Plus 2.0 array. The demographics of patients in the training and testing cohorts are in Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>, respectively. Tumor samples were compared to each other to minimize stromal and myometrial contamination as well as female-specific genes. A multidimensional scaling (MDS) plot using the whole transcriptome showed that the mRNA profiles of normal and cancerous tissues are different (Figure <xref ref-type="fig" rid="F1">1A</xref>). We then searched for genes distinguishing early and late EECs according to a statistical pipeline we used [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. A total of 678 probe sets could differentiate early and late stage samples, as well as discriminate 23 normal endometrium and 33 tumor tissues (Figure <xref ref-type="fig" rid="F1">1B</xref>; the positive false discovery rate (pFDR) cutoff q values are shown).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of 34 EEC patients used in the training cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">GSE No.</th><th align="left">TNM</th><th align="left">FIGO stage</th><th align="left">Histology</th><th align="left">FIGO grade</th><th align="left">Patient Age</th><th align="left">Ethnic Background</th></tr></thead><tbody><tr><td align="left" colspan="7"><bold><italic>(Isolation site: Endometrium)</italic></bold></td></tr><tr><td align="left">GSM117600</td><td align="left">T1aN0M0</td><td align="left">1A</td><td align="left">Adenocarcinoma</td><td align="left">1</td><td align="left">60-70</td><td align="left">Asian</td></tr><tr><td align="left">GSM152644</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM152660</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">40-50</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM137960</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM137968</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM137980</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">3</td><td align="left">40-50</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117586</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">50-60</td><td align="left">African-American</td></tr><tr><td align="left">GSM117643</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">1</td><td align="left">70-80</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117667</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117703</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">50-60</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117704</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">50-60</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117722</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">70-80</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117724</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117739</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">3</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM89034</td><td align="left">T1bN0</td><td/><td align="left">Endometrioid</td><td align="left">2</td><td align="left">40-50</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM89089</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">1</td><td align="left">70-80</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM76499</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">70-80</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM76638</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117697</td><td align="left">T1cN0M0</td><td align="left">1C</td><td align="left">Endometrioid</td><td align="left">3</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM89076</td><td align="left">T1cN0M0</td><td align="left">1C</td><td align="left">Endometrioid</td><td align="left">3</td><td align="left">70-80</td><td align="left">African Indian</td></tr><tr><td align="left">GSM76507</td><td align="left">T1cN0M0</td><td align="left">1C</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM137955</td><td align="left">T2aN0M0</td><td align="left">2A</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">60-70</td><td align="left">African-American</td></tr><tr><td align="left">GSM102425</td><td align="left">T2bN0M0</td><td align="left">2B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">50-60</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM102444</td><td align="left">T2bN0M0</td><td align="left">2B</td><td align="left">Endometrioid</td><td align="left">1</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM46912</td><td align="left">T2bN0M0</td><td align="left">2B</td><td align="left">Endometrioid</td><td align="left">1</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">GSM117708</td><td align="left">T3aN0M0</td><td align="left">3A</td><td align="left">Endometrioid</td><td align="left">3</td><td align="left">70-80</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117712</td><td align="left">T3aN0M0</td><td align="left">3A</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM38067</td><td align="left">T3aN0M0</td><td align="left">3A</td><td align="left">Endometrioid</td><td align="left">3</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM38084</td><td align="left">T4NXM0</td><td align="left">4A</td><td align="left">Endometrioid</td><td align="left">3</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM89087</td><td align="left">T3aNXM1 (*)</td><td align="left">4B</td><td align="left">Endometrioid</td><td align="left">3</td><td align="left">80-90</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM46867</td><td align="left">T3aN1M1 (**)</td><td align="left">4B</td><td align="left">Endometrioid</td><td align="left">3</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left" colspan="7"><bold><italic>(Isolation site: outside endometrium)</italic></bold></td></tr><tr><td align="left">GSM89079</td><td align="left">T3aNXM1($)</td><td align="left">4B</td><td align="left">Endometrioid</td><td align="left">3</td><td align="left">40-50</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM203686</td><td align="left">T3aN0M0 ($)</td><td align="left">3A</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM46932</td><td align="left">TXNXM1(@)</td><td align="left">4B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">50-60</td><td align="left">Caucasian</td></tr></tbody></table><table-wrap-foot><p>Endometrioid: Endometrioid carcinoma</p><p>*: Hepatic metastasis</p><p>**: Lymph node metastasis</p><p>$: Isolated from ovary</p><p>@: Isolated from abdominal wall fascia</p></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Characteristics of another 15 early EEC patients used in the testing set.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">GSE No.</th><th align="left">TNM</th><th align="left">FIGO stage</th><th align="left">Histology</th><th align="left">FIGO grade</th><th align="left">Patient Age</th><th align="left">Ethnic Background</th></tr></thead><tbody><tr><td align="left">GSM88952</td><td align="left">T1aN0M0</td><td align="left">1A</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">50-60</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM76487</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">1</td><td align="left">30-40</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM102469</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">1</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117579</td><td align="left">T1bN0MX</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">1</td><td align="left">80-90</td><td align="left">African-American</td></tr><tr><td align="left">GSM117589</td><td align="left">T1bN0MX</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">1</td><td align="left">80-90</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117767</td><td align="left">T1bN0MX</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM137961</td><td align="left">T1bN0MX</td><td align="left">1B</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117590</td><td align="left">T1cN0MX</td><td align="left">1C</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">70-80</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117729</td><td align="left">T2aN0M0</td><td align="left">2A</td><td align="left">Endometrioid</td><td align="left">1</td><td align="left">50-60</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM53176</td><td align="left">T2aN0MX</td><td align="left">2A</td><td align="left">Endometrioid</td><td align="left">1</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM117582</td><td align="left">T2aN0MX</td><td align="left">2A</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">40-50</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM88966</td><td align="left">T2aN1M0</td><td align="left">2A</td><td align="left">Endometrioid</td><td align="left">2</td><td align="left">80-90</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM53174</td><td align="left">T2bN0MX</td><td align="left">2B</td><td align="left">Adenosarcoma</td><td align="left">2</td><td align="left">60-70</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM76525</td><td align="left">T1aN0M0</td><td align="left">1A</td><td align="left">Endometrioid (Mix)</td><td align="left">3</td><td align="left">80-90</td><td align="left">Caucasian</td></tr><tr><td align="left">GSM76632</td><td align="left">T1bN0M0</td><td align="left">1B</td><td align="left">Adenocarcinoma</td><td align="left">2</td><td align="left">50-60</td><td align="left">Caucasian</td></tr></tbody></table><table-wrap-foot><p>Mix: Mixed endometrioid and serous adenocarcinoma</p></table-wrap-foot></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Identification of genes in different EECs</bold>. <bold>(A) </bold>A multidimensional scaling (MDS) plot drawn by all probe sets (~54600 ones) on the chip. Normal endometrium (Normal) and EECs of all 4 stages are included. Each spot represents an array. (<bold>B</bold>) A Venn diagram summarizing genes differentially expressed between normal and tumor tissues or between early (Stages 1 &#x00026; 2) and late (Stages 3 &#x00026; 4) EEC samples in the training cohort. (<bold>C</bold>) Narrowing down the existing gene signature using a machine learning strategy. When probe sets were ranked by signal-to-noise ratios (weights), the top 217 features was the largest panel to give the lowest error rate (i.e., a best classification effect; <italic>upper panel</italic>). (<bold>D</bold>) The discrimination ability of the 217-probeset signature. A prediction strength plot [25] shows the prediction strengths of the identified 217 probe sets in discriminating early from late EECs in the training cohort. Samples 1B and 2B denote 2 early EECs (Stages 1B and 2B, respectively) which express late EEC gene signatures. (<bold>E</bold>) A MDS plots using the above 217 probe sets. 2 misgrouped early EECs are indicated. (<bold>F</bold>) Signature evaluation by an independent testing data set. One Stage 1B case, which expresses late EEC gene signatures, is grouped into the late EEC area (separated by a red line).</p></caption><graphic xlink:href="1471-2164-10-613-1"/></fig><p>The discrimination ability of these 678 probe sets were evaluated by a supervised machine learning strategy, which combines the weighted voting algorithm and leave-one-out cross validation (LOOCV) [<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B25">25</xref>]. An error rate of 12.1% (2 out of 24 early cancers and 2 out of 9 late samples; P &#x0003c; 0.001 by permutation test) was found (Figure <xref ref-type="fig" rid="F1">1C</xref> and Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). However, we found the top 217 features (ranked by the weighted value of each probe set [<xref ref-type="bibr" rid="B25">25</xref>]) is the largest panel to have better discrimination ability than that of the 678-probeset signature (error rate 6.1% vs. 12.1%; Figure <xref ref-type="fig" rid="F1">1C</xref>, upper panel): 2 out of 24 early EEC tissues are classified into the late group while all 9 late ones are correct (Figure <xref ref-type="fig" rid="F1">1D</xref>). MDS analysis supports the superior classification power of these 217 probe sets: only 2 early samples express late EECs gene signatures and are grouped together with the late cases (Figure <xref ref-type="fig" rid="F1">1E</xref>). When applying these 217 probe sets on another independent testing data set containing 15 early EEC cases, 1 out of 15 early tissues (error rate 6.7%; P &#x0003c; 0.001 by permutation test) is misgrouped (Figure <xref ref-type="fig" rid="F1">1F</xref>).</p></sec><sec><title>In-depth exploration of EEC-related genes</title><p>To have a better idea how the filtrated genes distribute in early and late EECs, a gene expression heat map for those 217 probe sets was drawn (Figure <xref ref-type="fig" rid="F2">2</xref>). This heat map showed the unique gene expression patterns between early or late EEC tumor tissues. Consistent with the classification data obtained by prediction strength (PS) analysis in Figure <xref ref-type="fig" rid="F1">1D</xref>, hierarchical clustering showed that only 2 early cases in the training data set are misclassified (indicated by arrows; Figure <xref ref-type="fig" rid="F2">2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Molecular fingerprint of EEC subtypes</bold>. A heat map shows the 217 probes sets differentiating early and late EECs in the training data set, as well as discriminating normal endometrium and tumor tissues. Columns represent tumor samples; rows represent probe sets. In red, increased; in blue, decreased. Arrows indicates two early EECs which express a late EEC gene signature (black, Stage 1B; red, Stage 2B).</p></caption><graphic xlink:href="1471-2164-10-613-2"/></fig><p>Those 217 probe sets correspond to 177 known genes (with gene symbols) and 29 cDNAs, which have no gene symbols been assigned yet (all in Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>). Among them 58 genes/cDNAs are predominantly up in early ECCs while 25 being down (Figure <xref ref-type="fig" rid="F2">2</xref>). In contrast, 48 genes/cDNAs are particularly high in late EECs while another 75 being low (Figure <xref ref-type="fig" rid="F2">2</xref>). The details of known genes (especially those with known function) are in Tables <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T4">4</xref>, <xref ref-type="table" rid="T5">5</xref>, <xref ref-type="table" rid="T6">6</xref> and <xref ref-type="table" rid="T7">7</xref> respectively. Many of these genes, such as CD163 [<xref ref-type="bibr" rid="B26">26</xref>], MSR1 (CD204) [<xref ref-type="bibr" rid="B27">27</xref>], ERBB2 oncogene (also known as HER-2/neu) [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>], CSTA (stefin A) [<xref ref-type="bibr" rid="B30">30</xref>] and CCR1 [<xref ref-type="bibr" rid="B31">31</xref>], have been associated with tumor malignancy and poor patient outcomes in EEC or other cancers (Table <xref ref-type="table" rid="T3">3</xref>, bold). CD163 and MSR1 (macrophage scavenger receptor 1; CD204) are markers for M2 macrophages, whose infiltration in tumor lesions is correlated with the histological grade of the gliomas [<xref ref-type="bibr" rid="B27">27</xref>] (Table <xref ref-type="table" rid="T3">3</xref>, bold). These consistent findings support the reliability of our gene lists. We also validated our array data by performing immunohistochemical staining on Taiwanese EEC cases. ERBB2 was indeed more abundant in stages III and IV EEC tissues (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>ERBB2 protein expression in early and late EECs</bold>. (<bold>A</bold>) Representative immunohistochemical (IHC) staining of ERBB2 protein in primary EEC tissues. Staining results were graded as 0+: undetectable staining in &#x0003c;10% of the tumor cells; 2+: weak to moderate complete membrane staining (indicated by an arrow) in &#x0003c;10% of the tumor cells; 3+: strong complete membrane staining observed in &#x0003c;10% of the tumor cells. EEC cases were categorized as ERBB2-negative (scores 0 and 1+) or positive (scores 2+ and 3+). (<bold>B</bold>) A histogram summarizing the IHC results on 36 primary EEC tissues stained for ERBB2. A chi square test P value is shown. Case numbers and percentages are also indicated.</p></caption><graphic xlink:href="1471-2164-10-613-3"/></fig><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Up-regulated known genes in late stage EECs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Probe Set ID</th><th align="left">UniGene ID</th><th align="left">Gene Title</th><th align="left">Gene Symbol</th><th align="left">Chromosomal Location</th></tr></thead><tbody><tr><td align="left">213532_at</td><td align="left">Hs.404914</td><td align="left">ADAM metallopeptidase domain 17</td><td align="left">ADAM17</td><td align="left">chr2p25</td></tr><tr><td align="left">223660_at</td><td align="left">Hs.281342</td><td align="left">adenosine A3 receptor</td><td align="left">ADORA3</td><td align="left">chr1p13.2</td></tr><tr><td align="left">200966_x_at</td><td align="left">Hs.513490</td><td align="left">aldolase A, fructose-bisphosphate</td><td align="left">ALDOA</td><td align="left">chr16q22-q24</td></tr><tr><td align="left">205568_at</td><td align="left">Hs.104624</td><td align="left">aquaporin 9</td><td align="left">AQP9</td><td align="left">chr15q22.1-22.2</td></tr><tr><td align="left">224376_s_at</td><td align="left">Hs.584985</td><td align="left">chromosome 20 open reading frame 24</td><td align="left">C20orf24</td><td align="left">chr20q11.23</td></tr><tr><td align="left">224972_at</td><td align="left">Hs.472564</td><td align="left">chromosome 20 open reading frame 52</td><td align="left">C20orf52</td><td align="left">chr20q11.22</td></tr><tr><td align="left">200625_s_at</td><td align="left">Hs.370581</td><td align="left">CAP, adenylate cyclase-associated protein 1</td><td align="left">CAP1</td><td align="left">chr1p34.2</td></tr><tr><td align="left">201850_at</td><td align="left">Hs.516155</td><td align="left">capping protein (actin filament), gelsolin-like</td><td align="left">CAPG</td><td align="left">chr2p11.2</td></tr><tr><td align="left">205098_at</td><td align="left">Hs.301921</td><td align="left">chemokine (C-C motif) receptor 1</td><td align="left"><bold>CCR1</bold></td><td align="left">chr3p21</td></tr><tr><td align="left">203645_s_at</td><td align="left">Hs.504641</td><td align="left">CD163 molecule</td><td align="left"><bold>CD163</bold></td><td align="left">chr12p13.3</td></tr><tr><td align="left">209396_s_at</td><td align="left">Hs.382202</td><td align="left">chitinase 3-like 1 (cartilage glycoprotein-39)</td><td align="left">CHI3L1</td><td align="left">chr1q32.1</td></tr><tr><td align="left">204971_at</td><td align="left">Hs.518198</td><td align="left">cystatin A (stefin A)</td><td align="left"><bold>CSTA</bold></td><td align="left">chr3q21</td></tr><tr><td align="left">202190_at</td><td align="left">Hs.172865</td><td align="left">cleavage stimulation factor, subunit 1, 50kDa</td><td align="left">CSTF1</td><td align="left">chr20q13.31</td></tr><tr><td align="left">1554863_s_at</td><td align="left">Hs.473133</td><td align="left">docking protein 5</td><td align="left">DOK5</td><td align="left">chr20q13.2</td></tr><tr><td align="left">224336_s_at</td><td align="left">Hs.536535</td><td align="left">dual specificity phosphatase 16</td><td align="left">DUSP16</td><td align="left">chr12p13</td></tr><tr><td align="left">218282_at</td><td align="left">Hs.632276</td><td align="left">ER degradation enhancer mannosidase a-like 2</td><td align="left">EDEM2</td><td align="left">chr20q11.22</td></tr><tr><td align="left">216836_s_at</td><td align="left">Hs.446352</td><td align="left">v-erb-b2 erythroblastic leukemia viral oncogene</td><td align="left"><bold>ERBB2 (HER2)</bold></td><td align="left">chr17q11.2-q12</td></tr><tr><td align="left">203561_at</td><td align="left">Hs.78864</td><td align="left">IgG Fc fragment, IIa, receptor (CD32)</td><td align="left">FCGR2A</td><td align="left">chr1q23</td></tr><tr><td align="left">210889_s_at</td><td align="left">Hs.352642</td><td align="left">IgG Fc fragment, IIb, receptor (CD32)</td><td align="left">FCGR2B</td><td align="left">chr1q23</td></tr><tr><td align="left">210992_x_at</td><td align="left">Hs.78864</td><td align="left">IgG Fc fragment, IIc, receptor (CD32)</td><td align="left">FCGR2C</td><td align="left">chr1q23.3</td></tr><tr><td align="left">204007_at</td><td align="left">Hs.176663</td><td align="left">IgG Fc fragment, IIIb, receptor (CD16b)</td><td align="left">FCGR3B</td><td align="left">chr1q23</td></tr><tr><td align="left">217782_s_at</td><td align="left">Hs.268530</td><td align="left">G protein pathway suppressor 1</td><td align="left">GPS1</td><td align="left">chr17q25.3</td></tr><tr><td align="left">212355_at</td><td align="left">Hs.558466</td><td align="left">KIAA0323</td><td align="left">KIAA0323</td><td align="left">chr14q12</td></tr><tr><td align="left">203364_s_at</td><td align="left">Hs.410092</td><td align="left">KIAA0652</td><td align="left">KIAA0652</td><td align="left">chr11p11.2</td></tr><tr><td align="left">230252_at</td><td align="left">Hs.155538</td><td align="left">lysophosphatidic acid receptor 5</td><td align="left">LPAR5</td><td align="left">chr12p13.31</td></tr><tr><td align="left">228360_at</td><td align="left">Hs.357567</td><td align="left">hypothetical protein LOC130576</td><td align="left">LOC130576</td><td align="left">chr2q23.2</td></tr><tr><td align="left">226710_at</td><td align="left">Hs.105685</td><td align="left">similar to RIKEN cDNA C030006K11 gene</td><td align="left">MGC70857</td><td align="left">chr8q24</td></tr><tr><td align="left">224324_at</td><td align="left">Hs.131072</td><td align="left">maestro</td><td align="left">MRO</td><td align="left">chr18q21</td></tr><tr><td align="left">226241_s_at</td><td align="left">Hs.355935</td><td align="left">mitochondrial ribosomal protein L52</td><td align="left">MRPL52</td><td align="left">chr14q11.2</td></tr><tr><td align="left">214770_at</td><td align="left">Hs.632045</td><td align="left">macrophage scavenger receptor 1</td><td align="left"><bold>MSR1 (CD204)</bold></td><td align="left">chr8p22</td></tr><tr><td align="left">205460_at</td><td align="left">Hs.156832</td><td align="left">neuronal PAS domain protein 2</td><td align="left">NPAS2</td><td align="left">chr2q11.2</td></tr><tr><td align="left">209222_s_at</td><td align="left">Hs.473254</td><td align="left">oxysterol binding protein-like 2</td><td align="left">OSBPL2</td><td align="left">chr20q13.3</td></tr><tr><td align="left">210907_s_at</td><td align="left">Hs.478150</td><td align="left">programmed cell death 10</td><td align="left">PDCD10</td><td align="left">chr3q26.1</td></tr><tr><td align="left">238693_at</td><td align="left">Hs.529592</td><td align="left">Polyhomeotic like 3 (Drosophila)</td><td align="left">PHC3</td><td align="left">chr3q26.2</td></tr><tr><td align="left">203691_at</td><td align="left">Hs.112341</td><td align="left">peptidase inhibitor 3, skin-derived (SKALP)</td><td align="left">PI3</td><td align="left">chr20q12-q13</td></tr><tr><td align="left">226577_at</td><td align="left">Hs.593811</td><td align="left">Presenilin 1 (Alzheimer diseas 3)</td><td align="left">PSEN1</td><td align="left">chr14q24.3</td></tr><tr><td align="left">217811_at</td><td align="left">Hs.369052</td><td align="left">selenoprotein T</td><td align="left">SELT</td><td align="left">chr3q25.1</td></tr><tr><td align="left">222523_at</td><td align="left">Hs.401388</td><td align="left">SUMO1/sentrin/SMT3 specific peptidase 2</td><td align="left">SENP2</td><td align="left">chr3q27.2</td></tr><tr><td align="left">227518_at</td><td align="left">Hs.585896</td><td align="left">solute carrier family 35, member E1</td><td align="left">SLC35E1</td><td align="left">chr19p13.11</td></tr><tr><td align="left">1552671_a_at</td><td align="left">Hs.496057</td><td align="left">solute carrier family 9 (Na/H exchanger), 7</td><td align="left">SLC9A7</td><td align="left">chrXp11.3-11.23</td></tr><tr><td align="left">222410_s_at</td><td align="left">Hs.583855</td><td align="left">sorting nexin 6</td><td align="left">SNX6</td><td align="left">chr14q13.2</td></tr><tr><td align="left">203114_at</td><td align="left">Hs.25723</td><td align="left">Sjogren's syndrome/scleroderma autoantigen 1</td><td align="left">SSSCA1</td><td align="left">chr11q13.1</td></tr><tr><td align="left">223478_at</td><td align="left">Hs.530373</td><td align="left">translocase of inner mitochondrial 8 homolog B</td><td align="left">TIMM8B</td><td align="left">chr11q23.1-q23.2</td></tr><tr><td align="left">212769_at</td><td align="left">Hs.287362</td><td align="left">transducin-like enhancer of split 3</td><td align="left">TLE3</td><td align="left">chr15q22</td></tr><tr><td align="left">204787_at</td><td align="left">Hs.8904</td><td align="left">V-set and immunoglobulin domain containing 4</td><td align="left">VSIG4</td><td align="left">chrXq12-q13.3</td></tr><tr><td align="left">221247_s_at</td><td align="left">Hs.900069</td><td align="left">Williams-Beuren syndrome region 16</td><td align="left">WBSCR16</td><td align="left">chr7q11.23</td></tr><tr><td align="left">202939_at</td><td align="left">Hs.591501</td><td align="left">zinc metallopeptidase (STE24 homolog, yeast)</td><td align="left">ZMPSTE24</td><td align="left">chr1p34</td></tr><tr><td align="left">219050_s_at</td><td align="left">Hs.121025</td><td align="left">zinc finger, HIT type 2</td><td align="left">ZNHIT2</td><td align="left">chr11q13</td></tr></tbody></table></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Down-regulated known genes in late stage EECs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Probe Set ID</th><th align="left">UniGene ID</th><th align="left">Gene Title</th><th align="left">Gene Symbol</th><th align="left">Chromosomal Location</th></tr></thead><tbody><tr><td align="left">211224_s_at</td><td align="left">Hs.158316</td><td align="left">ATP-binding cassette, sub-family B, 11</td><td align="left">ABCB11</td><td align="left">chr2q24</td></tr><tr><td align="left">232948_at</td><td align="left">Hs.444414</td><td align="left">AF4/FMR2 family, member 3</td><td align="left">AFF3</td><td align="left">chr2q11.2-q12</td></tr><tr><td align="left">207133_x_at</td><td align="left">Hs.99691</td><td align="left">alpha-kinase 1</td><td align="left">ALPK1</td><td align="left">chr4q25</td></tr><tr><td align="left">1562271_x_at</td><td align="left">Hs.508738</td><td align="left">Rho guanine nucleotide exchange factor 7</td><td align="left">ARHGEF7</td><td align="left">chr13q34</td></tr><tr><td align="left">243899_at</td><td align="left">Hs.579108</td><td align="left">ADP-ribosylation factor-like 17 pseudogene 1</td><td align="left">ARL17P1</td><td align="left">chr17q21.32</td></tr><tr><td align="left">211076_x_at</td><td align="left">Hs.143766</td><td align="left">Atrophin 1</td><td align="left">ATN1</td><td align="left">chr12p13.31</td></tr><tr><td align="left">214256_at</td><td align="left">Hs.128041</td><td align="left">ATPase, Class V, type 10A</td><td align="left">ATP10A</td><td align="left">chr15q11.2</td></tr><tr><td align="left">237716_at</td><td align="left">Hs.434253</td><td align="left">Chromosome 9 open reading frame 3</td><td align="left">C9orf3</td><td align="left">chr9q22.32</td></tr><tr><td align="left">233844_at</td><td align="left">Hs.522805</td><td align="left">CD99 molecule-like 2</td><td align="left">CD99L2</td><td align="left">chrXq28</td></tr><tr><td align="left">243640_x_at</td><td align="left">Hs.127411</td><td align="left">CDC14 cell division cycle 14 homolog A</td><td align="left">CDC14A</td><td align="left">chr1p21</td></tr><tr><td align="left">233630_at</td><td align="left">Hs.472027</td><td align="left">CDP-diacylglycerol synthase 2</td><td align="left">CDS2</td><td align="left">chr20p13</td></tr><tr><td align="left">210701_at</td><td align="left">Hs.461361</td><td align="left">craniofacial development protein 1</td><td align="left">CFDP1</td><td align="left">chr16q22.2-q22.3</td></tr><tr><td align="left">238863_x_at</td><td align="left">Hs.130849</td><td align="left">Component of oligomeric golgi complex 8</td><td align="left">COG8</td><td align="left">chr16q22.1</td></tr><tr><td align="left">215377_at</td><td align="left">Hs.501345</td><td align="left">C-terminal binding protein 2</td><td align="left">CTBP2</td><td align="left">chr10q26.13</td></tr><tr><td align="left">1561616_a_at</td><td align="left">Hs.591570</td><td align="left">dynein, axonemal, heavy polypeptide 6</td><td align="left">DNAH6</td><td align="left">chr2p11.2</td></tr><tr><td align="left">1560042_at</td><td align="left">Hs.591566</td><td align="left">family with sequence similarity 82, A</td><td align="left">FAM82A</td><td align="left">chr2p22.2</td></tr><tr><td align="left">243588_at</td><td align="left">Hs.403917</td><td align="left">FERM, RhoGEF &#x00026; pleckstrin domain protein 1</td><td align="left">FARP1</td><td align="left">chr13q32.2</td></tr><tr><td align="left">243876_at</td><td align="left">Hs.189409</td><td align="left">Formin binding protein 1</td><td align="left">FNBP1</td><td align="left">chr9q34</td></tr><tr><td align="left">1560094_at</td><td align="left">Hs.155090</td><td align="left">Guanine nucleotide binding protein, &#x003b2; 5</td><td align="left">GNB5</td><td align="left">chr15q21.2</td></tr><tr><td align="left">210855_at</td><td align="left">Hs.467733</td><td align="left">GREB1 protein</td><td align="left">GREB1</td><td align="left">chr2p25.1</td></tr><tr><td align="left">1557289_s_at</td><td align="left">Hs.334930</td><td align="left">GTF2I repeat domain containing 2</td><td align="left">GTF2IRD2</td><td align="left">chr7q11.23</td></tr><tr><td align="left">232889_at</td><td align="left">Hs.620129</td><td align="left">glucuronidase, beta pseudogene 1</td><td align="left">GUSBP1</td><td align="left">chr5q13.2</td></tr><tr><td align="left">1555685_at</td><td align="left">Hs.463511</td><td align="left">Hexose-6-phosphate dehydrogenase</td><td align="left">H6PD</td><td align="left">chr1p36</td></tr><tr><td align="left">240482_at</td><td align="left">Hs.519632</td><td align="left">Histone deacetylase 3</td><td align="left">HDAC3</td><td align="left">chr5q31</td></tr><tr><td align="left">1559600_at</td><td align="left">Hs.632767</td><td align="left">Hypermethylated in cancer 2</td><td align="left">HIC2</td><td align="left">chr22q11.21</td></tr><tr><td align="left">1557329_at</td><td align="left">Hs.371350</td><td align="left">Holocarboxylase synthetase</td><td align="left">HLCS</td><td align="left">chr21q22.1</td></tr><tr><td align="left">1553111_a_at</td><td align="left">Hs.534040</td><td align="left">kelch repeat and BTB domain containing 6</td><td align="left">KBTBD6</td><td align="left">chr13q14.11</td></tr><tr><td align="left">231875_at</td><td align="left">Hs.374201</td><td align="left">kinesin family member 21A</td><td align="left">KIF21A</td><td align="left">chr12q12</td></tr><tr><td align="left">232814_x_at</td><td align="left">Hs.20107</td><td align="left">Kinesin 2</td><td align="left">KNS2</td><td align="left">chr14q32.3</td></tr><tr><td align="left">242112_at</td><td align="left">Hs.631954</td><td align="left">LSM11, U7 small nuclear RNA associated</td><td align="left">LSM11</td><td align="left">chr5q33.3</td></tr><tr><td align="left">232418_at</td><td align="left">Hs.30824</td><td align="left">leucine zipper transcription factor-like 1</td><td align="left">LZTFL1</td><td align="left">chr3p21.3</td></tr><tr><td align="left">1560033_at</td><td align="left">Hs.167531</td><td align="left">Methylcrotonoyl-Coenzyme A carboxylase 2</td><td align="left">MCCC2</td><td align="left">chr5q12-q13</td></tr><tr><td align="left">216783_at</td><td align="left">Hs.187866</td><td align="left">Neuroplastin</td><td align="left">NPTN</td><td align="left">chr15q22</td></tr><tr><td align="left">217802_s_at</td><td align="left">Hs.632458</td><td align="left">nuclear casein kinase and CDK substrate 1</td><td align="left">NUCKS1</td><td align="left">chr1q32.1</td></tr><tr><td align="left">232644_x_at</td><td align="left">Hs.518750</td><td align="left">OCIA domain containing 1</td><td align="left">OCIAD1</td><td align="left">chr4p11</td></tr><tr><td align="left">233270_x_at</td><td align="left">Hs.491148</td><td align="left">Pericentriolar material 1</td><td align="left">PCM1</td><td align="left">chr8p22-p21.3</td></tr><tr><td align="left">1558695_at</td><td align="left">Hs.188614</td><td align="left">Pleckstrin homology domain containing, A5</td><td align="left">PLEKHA5</td><td align="left">chr12p12</td></tr><tr><td align="left">233458_at</td><td align="left">Hs.460298</td><td align="left">polymerase (RNA) III polypeptide E</td><td align="left">POLR3E</td><td align="left">chr16p12.1</td></tr><tr><td align="left">1566541_at</td><td align="left">Hs.580351</td><td align="left">Protein kinase C, epsilon</td><td align="left">PRKCE</td><td align="left">chr2p21</td></tr><tr><td align="left">235004_at</td><td align="left">Hs.519904</td><td align="left">RNA binding motif protein 24</td><td align="left">RBM24</td><td align="left">chr6p22.3</td></tr><tr><td align="left">212044_s_at</td><td align="left">Hs.523463</td><td align="left">Ribosomal protein L27a</td><td align="left">RPL27A</td><td align="left">chr11p15</td></tr><tr><td align="left">215599_at</td><td align="left">Hs.535014</td><td align="left">SMA4</td><td align="left">SMA4</td><td align="left">chr5q13</td></tr><tr><td align="left">1556784_at</td><td align="left">Hs.551967</td><td align="left">Smith-Magenis syndrome region, candidate 7</td><td align="left">SMCR7</td><td align="left">chr17p11.2</td></tr><tr><td align="left">217704_x_at</td><td align="left">Hs.628886</td><td align="left">Suppressor of zeste 12 homolog pseudogene</td><td align="left">SUZ12P</td><td align="left">chr17q11.2</td></tr><tr><td align="left">215279_at</td><td align="left">Hs.499209</td><td align="left">Supervillin</td><td align="left">SVIL</td><td align="left">chr10p11.2</td></tr><tr><td align="left">207365_x_at</td><td align="left">Hs.435667</td><td align="left">thyroid hormone receptor, beta</td><td align="left">THRB</td><td align="left">chr3p24.2</td></tr><tr><td align="left">215428_at</td><td align="left">Hs.510833</td><td align="left">Tight junction protein 1 (zona occludens 1)</td><td align="left">TJP1</td><td align="left">chr15q13</td></tr><tr><td align="left">225004_at</td><td align="left">Hs.514211</td><td align="left">transmembrane protein 101</td><td align="left">TMEM101</td><td align="left">chr17q21.31</td></tr><tr><td align="left">242347_at</td><td align="left">Hs.8752</td><td align="left">Transmembrane protein 4</td><td align="left">TMEM4</td><td align="left">chr12q15</td></tr><tr><td align="left">238079_at</td><td align="left">Hs.576468</td><td align="left">tropomyosin 3</td><td align="left">TPM3</td><td align="left">chr1q21.2</td></tr><tr><td align="left">237513_at</td><td align="left">Hs.98609</td><td align="left">trypsin X3</td><td align="left">TRY1</td><td align="left">chr7q34</td></tr><tr><td align="left">1557571_at</td><td align="left">Hs.439381</td><td align="left">Vacuolar protein sorting 13 homolog D</td><td align="left">VPS13D</td><td align="left">chr1p36.22</td></tr><tr><td align="left">235551_at</td><td align="left">Hs.248815</td><td align="left">WD repeat domain 4</td><td align="left">WDR4</td><td align="left">chr21q22.3</td></tr><tr><td align="left">1555259_at</td><td align="left">Hs.444451</td><td align="left">sterile alpha motif and leucine zipper kinase AZK</td><td align="left">ZAK</td><td align="left">chr2q24.2</td></tr></tbody></table></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Up-regulated biological modules in late EECs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Biological Process</th><th align="left">%</th><th align="left">P-Value</th><th align="left">Genes</th></tr></thead><tbody><tr><td align="left">Regulation of catalytic activity</td><td align="left">12.50%</td><td align="left">0.0053</td><td align="left">DUSP16, <bold>CAP1</bold>, <bold>ADORA3</bold>, <bold>ERBB2</bold>, GPS1, <bold>PSEN1</bold></td></tr><tr><td align="left">Immune system process</td><td align="left">16.67%</td><td align="left">0.01694</td><td align="left">AQP9, FCGR2A, FCGR2B, FCGR2C, FCGR3B, CCR1, ERBB2, VSIG4</td></tr><tr><td align="left">Second-messenger-mediated signalling</td><td align="left">8.33%</td><td align="left">0.02006</td><td align="left"><bold>CAP1</bold>, <bold>ADORA3</bold>, ERBB2, <bold>CCR1</bold></td></tr><tr><td align="left">Regulation of MAP kinase activity</td><td align="left">6.25%</td><td align="left">0.02205</td><td align="left"><bold>DUSP16</bold>, ERBB2, <bold>GPS1</bold></td></tr><tr><td align="left">Cell surface receptor linked signal transduction</td><td align="left">20.83%</td><td align="left">0.02535</td><td align="left">TLE3, CAP1, SENP2, ADORA3, ERBB2, LPAR5, CCR1, ADAM17, PSEN1, SNX6</td></tr><tr><td align="left">Membrane organization and biogenesis</td><td align="left">8.33%</td><td align="left">0.0314</td><td align="left">CAP1, ZMPSTE24, MSR1, TIMM8B</td></tr></tbody></table></table-wrap><table-wrap id="T6" position="float"><label>Table 6</label><caption><p>Up-regulated known genes in early stage EECs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Probe Set ID</th><th align="left">UniGene ID</th><th align="left">Gene Title</th><th align="left">Gene Symbol</th><th align="left">Chromosomal Location</th></tr></thead><tbody><tr><td align="left">225054_x_at</td><td align="left">Hs.293560</td><td align="left">Archaemetzincins-2</td><td align="left">AMZ2</td><td align="left">chr17q24.2</td></tr><tr><td align="left">209870_s_at</td><td align="left">Hs.525718</td><td align="left">amyloid beta (A4) precursor protein-binding A2</td><td align="left"><bold>APBA2</bold></td><td align="left">chr15q11-q12</td></tr><tr><td align="left">1560851_at</td><td align="left">Hs.351856</td><td align="left">chromosome 10 open reading frame 136</td><td align="left">C10orf136</td><td align="left">chr10q11.21</td></tr><tr><td align="left">234457_at</td><td align="left">Hs.512758</td><td align="left">chromosome 6 open reading frame 12</td><td align="left">C6orf12</td><td align="left">chr6p21.33</td></tr><tr><td align="left">1561271_at</td><td align="left">Hs.328147</td><td align="left">coiled-coil domain containing 144C</td><td align="left">CCDC144C</td><td align="left">chr17p11.2</td></tr><tr><td align="left">211156_at</td><td align="left">Hs.512599</td><td align="left">cyclin-dependent kinase inhibitor 2A (p16)</td><td align="left"><bold>CDKN2A</bold></td><td align="left">chr9p21</td></tr><tr><td align="left">220335_x_at</td><td align="left">Hs.268700</td><td align="left">esterase 31</td><td align="left">CES3</td><td align="left">chr16q22.1</td></tr><tr><td align="left">204373_s_at</td><td align="left">Hs.557659</td><td align="left">centrosomal protein 350kDa</td><td align="left">CEP350</td><td align="left">chr1p36.13-q41</td></tr><tr><td align="left">233502_at</td><td align="left">Hs.12723</td><td align="left">Contactin 3 (plasmacytoma associated)</td><td align="left">CNTN3</td><td align="left">chr3p26</td></tr><tr><td align="left">244187_at</td><td align="left">Hs.512181</td><td align="left">Chromosome X open reading frame 33</td><td align="left">CXorf33</td><td align="left">chrXq21.1</td></tr><tr><td align="left">229738_at</td><td align="left">Hs.577398</td><td align="left">dynein, axonemal, heavy polypeptide 10</td><td align="left">DNAH10</td><td align="left">chr12q24.31</td></tr><tr><td align="left">219651_at</td><td align="left">Hs.317659</td><td align="left">developmental pluripotency associated 4</td><td align="left"><bold>DPPA4</bold></td><td align="left">chr3q13.13</td></tr><tr><td align="left">1555118_at</td><td align="left">Hs.441145</td><td align="left">ectonucleoside tri-P diphosphohydrolase 3</td><td align="left">ENTPD3</td><td align="left">chr3p21.3</td></tr><tr><td align="left">206794_at</td><td align="left">Hs.390729</td><td align="left">v-erb-a erythroblastic leukemia viral oncogene</td><td align="left">ERBB4</td><td align="left">chr2q33.3-q34</td></tr><tr><td align="left">241252_at</td><td align="left">Hs.99480</td><td align="left">establishment of cohesion 1 homolog 2</td><td align="left"><bold>ESCO2</bold></td><td align="left">chr8p21.1</td></tr><tr><td align="left">209631_s_at</td><td align="left">Hs.406094</td><td align="left">G protein-coupled receptor 37</td><td align="left"><bold>GPR37</bold></td><td align="left">chr7q31</td></tr><tr><td align="left">229714_at</td><td align="left">Hs.171001</td><td align="left">heparan sulfate 6-O-sulfotransferase 3</td><td align="left">HS6ST3</td><td align="left">chr13q32.1</td></tr><tr><td align="left">213598_at</td><td align="left">Hs.533222</td><td align="left">Dimethyladenosine transferase</td><td align="left">HSA9761</td><td align="left">chr5q11-q14</td></tr><tr><td align="left">231500_s_at</td><td align="left">Hs.444600</td><td align="left">SLC7A5 pseudogene</td><td align="left">LAT1-3TM</td><td align="left">chr16p11.2</td></tr><tr><td align="left">232953_at</td><td align="left">Hs.566209</td><td align="left">hypothetical LOC400723</td><td align="left">LOC400723</td><td align="left">chr11p15.5</td></tr><tr><td align="left">239076_at</td><td align="left">Hs.520804</td><td align="left">Similar to cell division cycle 10 homolog</td><td align="left">LOC441220</td><td align="left">chr7p13</td></tr><tr><td align="left">1558579_at</td><td align="left">Hs.587089</td><td align="left">hypothetical protein LOC642691</td><td align="left">LOC642691</td><td align="left">chr2p11.1</td></tr><tr><td align="left">222159_at</td><td align="left">Hs.497626</td><td align="left">Plexin A2</td><td align="left">PLXNA2</td><td align="left">chr1q32.2</td></tr><tr><td align="left">226766_at</td><td align="left">Hs.13305</td><td align="left">roundabout, axon guidance receptor, 2</td><td align="left"><bold>ROBO2</bold></td><td align="left">chr3p12.3</td></tr><tr><td align="left">1569124_at</td><td align="left">Hs.267765</td><td align="left">similar to Leucine-rich repeat protein SHOC-2</td><td align="left">RP11-139H14.4</td><td align="left">chr13q14.12</td></tr><tr><td align="left">220232_at</td><td align="left">Hs.379191</td><td align="left">stearoyl-CoA desaturase 5</td><td align="left">SCD5</td><td align="left">chr4q21.22</td></tr><tr><td align="left">214257_s_at</td><td align="left">Hs.534212</td><td align="left">SEC22 vesicle trafficking protein homolog B</td><td align="left">SEC22B</td><td align="left">chr1q21.1</td></tr><tr><td align="left">242536_at</td><td align="left">Hs.205816</td><td align="left">Solute carrier family 17, member 1</td><td align="left">SLC17A1</td><td align="left">chr6p23-p21.3</td></tr><tr><td align="left">220551_at</td><td align="left">Hs.242821</td><td align="left">solute carrier family 17, member 6</td><td align="left">SLC17A6</td><td align="left">chr11p14.3</td></tr><tr><td align="left">1559208_at</td><td align="left">Hs.437696</td><td align="left">ST7 overlapping transcript 4 (non-coding RNA)</td><td align="left">ST7OT4</td><td align="left">chr7q31.1-7q31.2</td></tr><tr><td align="left">233251_at</td><td align="left">Hs.21379</td><td align="left">Spermatid perinuclear RNA binding protein</td><td align="left">STRBP</td><td align="left">chr9q33.3</td></tr><tr><td align="left">223751_x_at</td><td align="left">Hs.120551</td><td align="left">toll-like receptor 10</td><td align="left">TLR10</td><td align="left">chr4p14</td></tr><tr><td align="left">217797_at</td><td align="left">Hs.301412</td><td align="left">ubiquitin-fold modifier conjugating enzyme 1</td><td align="left">UFC1</td><td align="left">chr1q23.3</td></tr><tr><td align="left">229997_at</td><td align="left">Hs.515130</td><td align="left">vang-like 1 (van gogh, Drosophila)</td><td align="left"><bold>VANGL1</bold></td><td align="left">chr1p11-p13.1</td></tr><tr><td align="left">204590_x_at</td><td align="left">Hs.592009</td><td align="left">vacuolar protein sorting 33 homolog A</td><td align="left">VPS33A</td><td align="left">chr12q24.31</td></tr><tr><td align="left">232964_at</td><td align="left">Hs.488157</td><td align="left">Williams Beuren syndrome region 19</td><td align="left">WBSCR19</td><td align="left">chr7p13</td></tr><tr><td align="left">227621_at</td><td align="left">Hs.446091</td><td align="left">Wilms tumor 1 associated protein</td><td align="left">WTAP</td><td align="left">chr6q25-q27</td></tr><tr><td align="left">240296_at</td><td align="left">Hs.98322</td><td align="left">Zinc finger, A20 domain containing 1</td><td align="left">ZA20D1</td><td align="left">chr1q21.2</td></tr><tr><td align="left">226208_at</td><td align="left">Hs.593643</td><td align="left">zinc finger, SWIM-type containing 6</td><td align="left">ZSWIM6</td><td align="left">chr5q12.1</td></tr></tbody></table></table-wrap><table-wrap id="T7" position="float"><label>Table 7</label><caption><p>Down-regulated known genes in early stage EECs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Probe Set ID</th><th align="left">UniGene ID</th><th align="left">Gene Title</th><th align="left">Gene Symbol</th><th align="left">Chromosomal Location</th></tr></thead><tbody><tr><td align="left">215535_s_at</td><td align="left">Hs.409230</td><td align="left">1-acylglycerol-3-phosphate O-acyltransferase 1</td><td align="left">AGPAT1</td><td align="left">chr6p21.3</td></tr><tr><td align="left">202204_s_at</td><td align="left">Hs.295137</td><td align="left">autocrine motility factor receptor</td><td align="left">AMFR</td><td align="left">chr16q21</td></tr><tr><td align="left">212536_at</td><td align="left">Hs.478429</td><td align="left">ATPase, Class VI, type 11B</td><td align="left">ATP11B</td><td align="left">chr3q27</td></tr><tr><td align="left">220975_s_at</td><td align="left">Hs.201398</td><td align="left">C1q and tumor necrosis factor related protein 1</td><td align="left">C1QTNF1</td><td align="left">chr17q25.3</td></tr><tr><td align="left">224794_s_at</td><td align="left">Hs.495230</td><td align="left">cerebral endothelial cell adhesion molecule 1</td><td align="left">CEECAM1</td><td align="left">chr9q34.11</td></tr><tr><td align="left">1557394_at</td><td align="left">Hs.249600</td><td align="left">discs, large homolog-associated protein 4</td><td align="left">DLGAP4</td><td align="left">chr20q11.23</td></tr><tr><td align="left">211958_at</td><td align="left">Hs.369982</td><td align="left">insulin-like growth factor binding protein 5</td><td align="left">IGFBP5</td><td align="left">chr2q33-q36</td></tr><tr><td align="left">225303_at</td><td align="left">Hs.609291</td><td align="left">kin of IRRE like (Drosophila)</td><td align="left">KIRREL</td><td align="left">chr1q21-q25</td></tr><tr><td align="left">218717_s_at</td><td align="left">Hs.374191</td><td align="left">leprecan-like 1</td><td align="left">LEPREL1</td><td align="left">chr3q28</td></tr><tr><td align="left">209205_s_at</td><td align="left">Hs.436792</td><td align="left">LIM domain only 4</td><td align="left">LMO4</td><td align="left">chr1p22.3</td></tr><tr><td align="left">203506_s_at</td><td align="left">Hs.409226</td><td align="left">mediator of RNA polymerase II transcription 12</td><td align="left">MED12</td><td align="left">chrXq13</td></tr><tr><td align="left">207564_x_at</td><td align="left">Hs.405410</td><td align="left">O-linked N-acetylglucosamine transferase</td><td align="left">OGT</td><td align="left">chrXq13</td></tr><tr><td align="left">214484_s_at</td><td align="left">Hs.522087</td><td align="left">opioid receptor, sigma 1</td><td align="left">OPRS1</td><td align="left">chr9p13.3</td></tr><tr><td align="left">203244_at</td><td align="left">Hs.567327</td><td align="left">peroxisomal biogenesis factor 5</td><td align="left">PEX5</td><td align="left">chr12p13.3</td></tr><tr><td align="left">241916_at</td><td align="left">Hs.130759</td><td align="left">Phospholipid scramblase 1</td><td align="left">PLSCR1</td><td align="left">chr3q23</td></tr><tr><td align="left">229001_at</td><td align="left">Hs.601513</td><td align="left">Protein phosphatase 1, regulatory 3E</td><td align="left">PPP1R3E</td><td align="left">chr14q11.2</td></tr><tr><td align="left">208720_s_at</td><td align="left">Hs.282901</td><td align="left">RNA binding motif protein 39</td><td align="left">RBM39</td><td align="left">chr20q11.22</td></tr><tr><td align="left">209148_at</td><td align="left">Hs.388034</td><td align="left">retinoid &#x000d7; receptor, beta</td><td align="left">RXRB</td><td align="left">chr6p21.3</td></tr><tr><td align="left">209352_s_at</td><td align="left">Hs.13999</td><td align="left">SIN3 homolog B, transcription regulator (yeast)</td><td align="left">SIN3B</td><td align="left">chr19p13.11</td></tr><tr><td align="left">221500_s_at</td><td align="left">Hs.307913</td><td align="left">syntaxin 16</td><td align="left">STX16</td><td align="left">chr20q13.32</td></tr><tr><td align="left">220036_s_at</td><td align="left">Hs.272838</td><td align="left">syntaxin 6</td><td align="left">STX6</td><td align="left">chr1q25.3</td></tr><tr><td align="left">201110_s_at</td><td align="left">Hs.164226</td><td align="left">thrombospondin 1</td><td align="left">THBS1</td><td align="left">chr15q15</td></tr><tr><td align="left">221507_at</td><td align="left">Hs.631637</td><td align="left">transportin 2 (importin 3, karyopherin b 2b)</td><td align="left">TNPO2</td><td align="left">chr19p13.13</td></tr><tr><td align="left">208723_at</td><td align="left">Hs.171501</td><td align="left">ubiquitin specific peptidase 11</td><td align="left">USP11</td><td align="left">chrXp11.23</td></tr></tbody></table></table-wrap><p>To gain more insights into the functional consequences of differential gene expression, we performed gene set enrichment analysis for the filtrated genes. Signature probe sets were subjected into the Gene Ontology (GO) database search to find statistically over-represented functional groups within these genes. The biological processes being statistically overrepresented (P &#x0003c; 0.05) in late stage-enriched genes are shown in Table <xref ref-type="table" rid="T5">5</xref>. These predominant processes include those pertaining to immune system process, second-messenger-mediated signaling (genes also involved in cyclic nucleotide second messenger (P = 0.0306) are bold), MAP kinase activity (genes also involved in the inactivation of MAPK activity (P = 0.0459) are bold), membrane organization and biogenesis, regulation of catalytic activity (genes also involved in the positive regulation of catalytic activity (P = 0.0182) are bold), and cell surface receptor-linked signal transduction are significantly up (Table <xref ref-type="table" rid="T5">5</xref>).</p><p>For genes enriched in early EECs, CDKN2A (P16) tumor suppressor was found to be reverse correlated with EEC prognosis [<xref ref-type="bibr" rid="B32">32</xref>] (Table <xref ref-type="table" rid="T6">6</xref>, bold). Another tumor suppressor is APBA2 (amyloid beta (A4) precursor protein-binding, family A, member 2; also known as MINT2), which is frequently methylated and silent in colorectal carcinoma and gastric carcinoma [<xref ref-type="bibr" rid="B33">33</xref>]. Hypermethylation of GPR37 is also frequently found in acute myeloid leukemia [<xref ref-type="bibr" rid="B34">34</xref>]. In terms of oncogenes, ROBO2 (roundabout, axon guidance receptor, 2), a receptor of the SLIT2 axon guidance and cell migration growth factor, is associated with poor prognosis of breast cancer [<xref ref-type="bibr" rid="B35">35</xref>]. ESCO2 (establishment of cohesion 1 homolog 2) is tightly correlated with BRCA1-dependent and various cell-type specific carcinogenesis [<xref ref-type="bibr" rid="B36">36</xref>], and DAPP4 pluripotent factor is enriched in seminomas [<xref ref-type="bibr" rid="B37">37</xref>]. VANGL1 (also known as KITENIN or STB2) acts as an executor in colon cancer cells with regard to cell motility and thereby controls cell invasion, which may contribute to promoting metastasis [<xref ref-type="bibr" rid="B38">38</xref>]. The abundant expression of known oncogenes in early EECs also suggests the early EEC cases contain high percentage of epithelial tumor cells instead of merely stromal and myometrial contaminations.</p></sec><sec><title>A six-gene signature distinguishing early and late EECs</title><p>When evaluating the classification effect of filtrated genes, we noticed that the top 6 genes could already distinguish early and late EECs, and these 6 genes gave the same diagnostic power to that of the 217 probe sets in the training cohort (Figure <xref ref-type="fig" rid="F4">4A</xref>). The same two early cases (one Stage 1B and one Stage 2B) were misgrouped with the late ones (Figure <xref ref-type="fig" rid="F4">4B</xref>). When applying these 6 genes on the testing data set, a lowest error rate could also be achieved (Figure <xref ref-type="fig" rid="F4">4C</xref>, upper panel). Only 1 out of 15 early tissues (error rate 6.7%; P &#x0003c; 0.001 by permutation test) was misgrouped (Figure <xref ref-type="fig" rid="F4">4C</xref>, lower panel). The same Stage 1B sample was misclassified when either applied only these 6 genes or the entire 217 probe sets (Figure <xref ref-type="fig" rid="F1">1F</xref>). Thus, these 6 genes hold clinical potentials of being diagnostic biomarkers. These 6 genes are: (1) ATP-binding cassette, B (MDR/TAP), 11 (ABCB11) (2) Archaemetzincins-2 (AMZ2) (3) amyloid beta (A4) precursor protein-binding A2 (APBA2) (4) LIM domain only 4 (LMO4) (5) Hypothetical protein LOC647065 (LOC647065) and (6) Homo sapiens mRNA, clone IMAGE:5759975 (cDNA FLJ12258 fis) (Table <xref ref-type="table" rid="T8">8</xref>). AMZ and APBA2 are up-regulated in early EECs. ABCB11, LOC647065 and cDNA FLJ12258 fis are down in tumors, especially in late EECs, while LMO4 particularly down in early EECs.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>A six-gene signature dividing early and late EECs</bold>. (<bold>A</bold>) Further narrowing down the existing gene signature to fewer genes. When probe sets were ranked by their signal-to-noise ratios (weights), the top 6 features form the smallest panel which can give the best classification effect. (<bold>B</bold>) A prediction strength (PS) plot shows the prediction strength of these 6 genes. They give the same classification effect as that of the 217-probeset signature. (<bold>C</bold>) Signature evaluation by a testing data set. A lowest error rate (<italic>upper</italic>) and best classification effect (shown by a PS plot; <italic>lower panel</italic>) was achieved.</p></caption><graphic xlink:href="1471-2164-10-613-4"/></fig><table-wrap id="T8" position="float"><label>Table 8</label><caption><p>Gene annotations of the six-gene signature.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Probe Set ID</th><th align="left">UniGene ID</th><th align="left">Gene Title</th><th align="left">Gene Symbol</th><th align="left">Chromosomal Location</th></tr></thead><tbody><tr><td align="left">233113_at</td><td align="left">Hs.633901</td><td align="left">Homo sapiens, clone IMAGE:5759975, mRNA</td><td align="left">---</td><td align="left">---</td></tr><tr><td align="left">211224_s_at</td><td align="left">Hs.158316</td><td align="left">ATP-binding cassette, B (MDR/TAP), 11</td><td align="left">ABCB11</td><td align="left">chr2q24</td></tr><tr><td align="left">225054_x_at</td><td align="left">Hs.293560</td><td align="left">Archaemetzincins-2</td><td align="left">AMZ2</td><td align="left">chr17q24.2</td></tr><tr><td align="left">209870_s_at</td><td align="left">Hs.525718</td><td align="left">amyloid beta (A4) precursor protein-binding A2</td><td align="left">APBA2</td><td align="left">chr15q11-q12</td></tr><tr><td align="left">209205_s_at</td><td align="left">Hs.436792</td><td align="left">LIM domain only 4</td><td align="left">LMO4</td><td align="left">chr1p22.3</td></tr><tr><td align="left">239819_at</td><td align="left">Hs.624027</td><td align="left">Hypothetical protein LOC647065</td><td align="left">LOC647065</td><td align="left">chr2q23.1</td></tr></tbody></table></table-wrap></sec><sec><title>Re-activation of epithelial stem cell genes in advanced EECs</title><p>Since our main goal is to identify EpiSC genes in EECs, we compared the gene expression profiles of EEC tissues of all 4 stages to that of normal CD133+ EpiSCs [<xref ref-type="bibr" rid="B39">39</xref>]. When the 217 genes distinguishing early and late EECs were applied to compare the relationships between EECs and EpiSCs, clearly EpiSCs have a closest relationship to late EECs (Figure <xref ref-type="fig" rid="F5">5A</xref>). This impression is strengthened by calculating the average linkage distances between sample groups. Compared with early EECs, EEC of both Stages III and IV are closer to EpiSCs to a similar extent (Figure <xref ref-type="fig" rid="F5">5B</xref>), suggesting the re-expression of EpiSC features in late EECs. A total of 26 EpiSC genes are overexpressed in advanced EECs (Figure <xref ref-type="fig" rid="F5">5C</xref>). Also, genes down-regulated in late EECs (the 77 probe sets in Figure <xref ref-type="fig" rid="F2">2</xref>) are absence in EpiSCs (Figure <xref ref-type="fig" rid="F5">5D</xref>). Most early EECs clustered together and expressed the intermediate level of EpiSC genes (Figure <xref ref-type="fig" rid="F5">5C-D</xref>), consistent with the distances analysis result in Figure <xref ref-type="fig" rid="F5">5B</xref>.</p><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Expression of EpiSC gene patterns in EECs, especially late ones</bold>. (<bold>A</bold>) Relationships between normal endometrium, EECs of different stages in the training data set and epithelial stem cells (EpiSCs). This MDS plot was drawn by the 217 features differentiating early and late EECs. (<bold>B</bold>) Average linkage distances between tissues and EpiSCs. The same 217 probe sets were used. The confidence limits shown represent the standard error. (<bold>C</bold>) A heat map shows genes overexpressed in both EpiSCs and late EECs. Gene symbols of these genes are shown. Genes associate with tumor malignancy or stem cell biology are underlined. (<bold>D</bold>) A heat map shows the distribution patterns of the 77 probe sets down-regulated in late EECs. These genes are also absence in EpiSCs.</p></caption><graphic xlink:href="1471-2164-10-613-5"/></fig></sec></sec><sec><title>Discussion</title><p>EEC still ranks one of the most fatal female cancers worldwide and disease progression very often accompany with worse clinical outcomes and treatment failure. Identifying genes or canonical pathways associated with advanced cancer can help to unmask the mechanisms of tumor malignancy as well as provide us with novel drug targets. It has been recognized clinically that cancer cells, especially the advanced and metastatic ones, possess characters reminiscent of those of normal stem cells. The degree of stem cell gene expression correlates with pivotal tumor features and patient prognosis [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Hence, identifying shared genes between late EECs and stem cells will provide new insights into cancer biology, as well as new prognosis markers and therapeutic targets. In this study, we identified a 217-probeset signature which could distinguish late (stages III-IV) from early (stages I-II) EECs (Figure <xref ref-type="fig" rid="F1">1</xref>). More low stage disease array data than high stage ones were obtained, which may partly due to the fact that the early diagnosis takes place in almost 90% of EEC clinically. We combined primary and metastatic late EEC samples in one group since their molecular profiles are indistinguishable (not shown). Prostate EpiSCs were used as a comparative group since array data for endometrial stem cells is not available yet. Nevertheless, prostate CD133+ cells are still epithelial stem cells and therefore good controls. Other EpiSC data should reproduce part of our findings.</p><p>Our results reveal a previously unaware link between genes associated with EpiSC identity and the histopathological traits of EECs. It is possible that these genes contribute to the stem cell-like phenotypes of late EECs. A total of 26 EpiSC genes were found overexpressed in late EECs (Figure <xref ref-type="fig" rid="F5">5C</xref>), and genes down-regulated in late EECs (Figure <xref ref-type="fig" rid="F2">2</xref>; 77 probe sets) are also absence in EpiSCs (Figure <xref ref-type="fig" rid="F5">5D</xref>). Among those 26 overexpressed genes there are famous oncogenes or stemness genes (Figure <xref ref-type="fig" rid="F5">5C</xref>, underlined). ADAM17 (A Disintegrin and A Metalloproteinase 17), also known as tumor necrosis factor-alpha converting enzyme (TACE) or less commonly CD156q, is a therapeutic target in multiple diseases since major contemporary pathologies like cancer, inflammatory and vascular diseases seem to be connected to its cleavage abilities [<xref ref-type="bibr" rid="B40">40</xref>]. CAP1 (adenylate cyclase-associated protein 1) overexpressed in pancreatic cancers is involved in cancer cell motility [<xref ref-type="bibr" rid="B41">41</xref>]. CAPG (capping protein (actin filament), gelsolin-like) also contributes in the motility of pancreatic cancer cells [<xref ref-type="bibr" rid="B42">42</xref>]. PDCD10 (CCM3) is involved in cerebral cavernous malformations (CCM) [<xref ref-type="bibr" rid="B43">43</xref>] and is found to interact with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway [<xref ref-type="bibr" rid="B44">44</xref>]. PSEN1 (presenilin 1) is involved in apoptosis, overexpressed in high-risk patients with stage I non-small cell lung cancer (NSCLC), and is in a prognosis signature of NSCLC patients [<xref ref-type="bibr" rid="B45">45</xref>]. SENP2 (SUMO-specific protease 2) is highly expressed in trophoblast cells that are required for placentation, and targeted disruption of SENP2 in mice reveals its essential role in development of all three trophoblast layers via modulating the Mdm2-p53 pathway [<xref ref-type="bibr" rid="B46">46</xref>]. The appearance of these known oncogenes or stemness genes in our data supports the reliability of our gene lists. The roles of EpiSC genes in both epithelial stem cell biology and EEC malignancy will be addressed further.</p><p>Several genes were previous suggested to be tumor suppressors. CSTA (cystatin A, or stefin A), a cysteine proteinases inhibitor, is implicated in preventing local and metastatic tumor spread of cancers. The risk of disease recurrence and disease-related death was thus higher in patients with low CSTA in patients with squamous cell carcinoma of the head and neck [<xref ref-type="bibr" rid="B30">30</xref>]. NPAS2 (neuronal PAS domain protein 2) is a circadian gene as well as a putative tumor suppressor involved in DNA damage response [<xref ref-type="bibr" rid="B47">47</xref>]. PHC3 (polyhomeotic homolog 3), a component of the hPRC-H complex, associates with E2F6 during G0 and is lost in osteosarcoma tumors [<xref ref-type="bibr" rid="B48">48</xref>]. Validating their expression in different stages of EECs by further immunohistochemstry study will not only provide novel malignancy mechanisms but will also present new drug targets.</p><p>In the past few years, much effort has been put to explore the mechanisms and additional molecular markers for predicting prognosis of EECs by using high-throughput genomics technology. Gene expression microarray (GEM) is a popular platform among all of those high-throughput genomics techniques. In this study we applied GEM and machine learning algorithms to filtrate out a 217-probeset signature for disease diagnosis. Many of the filtrated genes have been linked to tumor progression and malignancy, supporting the reliability of our array data. Moreover, we narrowed down this 217-probeset profile to a six-gene mini-signature for the differentiation of early to late EECs in the training set. This signature can be validated by an independent testing cohort (Figure <xref ref-type="fig" rid="F4">4</xref>). Owing to the small gene number of this signature, it is now possible to check their mRNA levels in patient tissues by real-time PCR in regular clinical labs. Recently a five-gene profile and a five-microRNA signature are identified for the prediction of clinical outcomes in non-small-cell lung cancer [<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B50">50</xref>]. Whether our six-gene signature can be correlated with relapse-free and overall survival among patients with EEC is unclear and awaited to be elucidated. Also, whether the protein expression levels of these 6 genes correlate with those of mRNAs is unclear. Since most of the patients in either training or testing data set were Caucasian (Table <xref ref-type="table" rid="T1">1</xref>), whether this gene signature can be applied in patients with various genetic backgrounds should also be studied.</p><p>In our datasets we noticed that few early EEC cases expressed already late EEC genes and therefore could not be classified correctly (Figs. <xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F2">2</xref>). Since patients with late and metastatic EEC tend to have poor prognosis, whether these unusual early cases possess worse clinical outcomes is an interesting issue. It has been suggested that prognosis potential of human tumors is inherited in early lesions. For example, the gene expression patterns in metastatic colorectal carcinoma are readily distinguishable from those associated with <italic>in situ </italic>tumors [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B51">51</xref>]. A subset of primary tumors resembled metastatic tumors with respect to this gene-expression signature [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B51">51</xref>]. Very recently Varmus and colleagues showed that when untransformed mouse mammary cells were introduced into the systemic circulation of a mouse, those cells can bypass transformation at the primary site, form long-term residence in the lungs but do not form ectopic tumors [<xref ref-type="bibr" rid="B52">52</xref>]. Husemann et al. also observed that systemic spread can be an early step in breast cancer. Tumor cells can disseminate systemically from earliest epithelial alterations and form and micrometastasis in bone marrow and lungs [<xref ref-type="bibr" rid="B53">53</xref>]. Therefore, release from dormancy of early-disseminated cancer cells may frequently account for metachronous metastasis. The metastatic potential of human tumors is encoded in the bulk of a primary tumor and, at least in a subset of patients, metastatic capability in cancers is an inherent feature. Our EEC gene signatures therefore hold the potential of being a novel prognosis panel. More advanced therapy and clinical follow-up should be applied on early stage patients with molecular feature similar to that of EpiSC.</p><p>In advanced EECs, tumor tissues express more genes abundant in CD133+ EpiSC and acquired a stem cell trait (Figure <xref ref-type="fig" rid="F5">5</xref>). The expression of these EpiSC genes in late EECs may due to the re-expression of EpiSC features in late stage EECs, i.e., further mutations and stem cell gene reactivation in certain early EECs. The intermediate EpiSC gene expression level in early EECs supports this point (Figure <xref ref-type="fig" rid="F5">5A</xref> &#x00026;<xref ref-type="fig" rid="F5">5C-D</xref>). Recent studies demonstrated that EMT contributes to the acquisition of stem cell traits in cancer cells and the induction of EMT inducer Snail results in stemness gene expression [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Whether EMT also contributes in EEC progression and metastasis is an interesting issue to follow. However, we did not rule out the possibility that certain late EECs may arise from an independent rapidly progressing cancer utilizing stemness molecular pathways. According to the tumor stem cell theory, cancer cells may be originated from different cancer stem cells acquiring distinctive oncogenic mutations. Certain early EECs have the capacity to progress to late stage disease may due to a mechanism that they arose from the same mutated progenitor cells as late EECs. The observation that several early EEC cases express EpiSC genes already (Figure <xref ref-type="fig" rid="F1">1D</xref> &#x00026;<xref ref-type="fig" rid="F5">5C</xref>) favors the later hypotheses. These 2 situations may both exist <italic>in vivo</italic>, but our profiling work cannot favor any of them yet. Nevertheless, genes filtrated here will provide clinicians novel prognosis markers and therapeutic targets.</p></sec><sec><title>Conclusions</title><p>In summary, here we reveal distinct epithelial stem cell traits and gene expression patterns in late EECs and some of these genes hold the potential of being novel drug targets. Drugs targeting MAP kinase pathway, for example, may be applied for the treatment of late EEC since this canonical pathway is significantly up in late EECs (Table <xref ref-type="table" rid="T5">5</xref>). Since applying a statistical analysis of gene ontology terms is the reliance on prior knowledge of the biological activity of each differentially expressed gene, the enrichment of genes associated with specific pathways may be a consequence of intense research in such areas. Hence, new canonical pathways may still exist and may serve as candidate therapeutic targets. Function of the filtrated KIAA (such as KIAA0323, Figure <xref ref-type="fig" rid="F5">5C</xref>) and LOC series of anonymous ESTs (such as C20orf24, Figure <xref ref-type="fig" rid="F5">5C</xref>) in Tables <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T4">4</xref>, <xref ref-type="table" rid="T5">5</xref>, <xref ref-type="table" rid="T6">6</xref>, <xref ref-type="table" rid="T7">7</xref> should be studied and their roles in tumor malignancy, chemoresistance and EpiSC stemness are awaited to be elucidated. Further studies to prove the prognosis values and therapeutic potentials of the identified genes, especially those also present in epithelial stem cells, should lead to a better understanding of EEC and EpiSC biology and the susceptibilities of late EECs to treatment.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Microarray data sets</title><p>All array data were implemented by the Affymetrix&#x02122; HG-U133 Plus 2.0 GeneChip. Array data of normal CD133+ epithelial stem cells, which were used as a normal counterpart of cancer stem cells [<xref ref-type="bibr" rid="B39">39</xref>], isolated from benign prostatic hyperplasia were downloaded from the ArrayExpress database at the European Bioinformatics Institute (<ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/microarray-as/ae/">http://www.ebi.ac.uk/microarray-as/ae/</ext-link>; Accession No. E-MEXP-993; array data files 1325504978.cel, 1325505459.cel and 1325505089.cel were used).</p><p>The gene expression profiles of EEC tissues of different stages were generated by the International Genomics Consortium (IGC) under the expO (Expression Project for Ontology) project and were downloaded from Gene Expression Omnibus (GEO <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link>; GSE2109). EEC array data were divided into training (n = 33; incl. all 4 stages) and testing cohorts (n = 15) (details in Table <xref ref-type="table" rid="T1">1</xref>). Array data of normal endometrium controls were from a Human body index dataset in GEO (GSE7307).</p></sec><sec><title>Array data processing</title><p>Feature selection was performed as previously described [<xref ref-type="bibr" rid="B22">22</xref>]. Briefly, the default robust multichip average (RMA) settings were used to background correct, normalize and summarize all expression values using the 'affy' package of the Bioconductor suite of software <ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org/">http://www.bioconductor.org/</ext-link> for the R statistical programming language. A t-statistic was calculated as normal for each gene and a <italic>p</italic>-value then calculated using a modified permutation test in the "LIMMA" package [<xref ref-type="bibr" rid="B22">22</xref>]. To control the multiple testing errors, a false discovery rate (FDR) algorithm was then applied to these <italic>p</italic>-values to calculate a set of <italic>q</italic>-values: thresholds of the expected proportion of false positives, or false rejections of the null hypothesis [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B54">54</xref>]. Gene annotation was performed by the ArrayFusion web tool <ext-link ext-link-type="uri" xlink:href="http://microarray.ym.edu.tw/tools/arrayfusion/">http://microarray.ym.edu.tw/tools/arrayfusion/</ext-link>[<xref ref-type="bibr" rid="B55">55</xref>]. Gene enrichment analysis was performed by the Gene Ontology (GO) database using the DAVID Bioinformatics Resources 2008 interface <ext-link ext-link-type="uri" xlink:href="http://david.abcc.ncifcrf.gov/">http://david.abcc.ncifcrf.gov/</ext-link>, a graph theory evidence-based method to agglomerate gene or protein identifiers [<xref ref-type="bibr" rid="B56">56</xref>,<xref ref-type="bibr" rid="B57">57</xref>].</p></sec><sec><title>Bioinformatics analysis</title><p>The discrimination power of filtrated genes was evaluated by a machine-learning approach combining the weighted voting algorithm [<xref ref-type="bibr" rid="B24">24</xref>] and leave-one-out cross-validation (LOOCV). This approach has been integrated in our Java tool <ext-link ext-link-type="uri" xlink:href="http://microarray.ym.edu.tw/tools/set/">http://microarray.ym.edu.tw/tools/set/</ext-link>[<xref ref-type="bibr" rid="B25">25</xref>]. In brief, the uploaded genes are ranked according to the absolute values of corresponding signal-to-noise scores [<xref ref-type="bibr" rid="B24">24</xref>] in a descending order. Genes are included into a signature one at a time based on the order of ranking. The error rate for each new signature is estimated by the weighted voting algorithm and LOOCV and can be monitored by an error rate distribution plot [<xref ref-type="bibr" rid="B25">25</xref>]. Based on the error rate information, we then selected an appropriate composition of discriminating genes with the lowest error rate. Once a signature is defined, the result of prediction strength (PS) analysis for each sample was shown. The PS values range from -1 to +1, where higher absolute values reflect stronger predictions [<xref ref-type="bibr" rid="B25">25</xref>]. An overview of the results for samples in different groups was then illustrated by a PS plot [<xref ref-type="bibr" rid="B25">25</xref>].</p><p>Classical multidimensional scaling (MDS) is performed by the standard function of the R program to provide a visual impression of how the various sample groups are related. The average linkage distance between samples is calculated by the Pearson correlation subtracted from unity to provide bounded distances in the range (0, 2), as described in our previous study [<xref ref-type="bibr" rid="B22">22</xref>]. The distance between two groups of samples is calculated using the average linkage measure (the mean of all pair-wise distances (linkages) between members of the two groups concerned). The standard error of the average linkage distance between two groups (the standard deviation of pair-wise linkages divided by the square root of the number of linkages) is quoted when inter-group distances are compared in the text.</p></sec><sec><title>Immunohistochemical staining</title><p>Staining was performed on formalin-fixed, paraffin-embedded specimens using anti-ERBB2 primary antibody (DAKO, Carpinteria, CA, USA). Scoring was performed as following. 0: undetectable staining or membrane staining in &#x0003c;10% of the tumor cells. 1+: faint and incomplete membrane staining in &#x0003e;10% of the tumor cells; 2+: weak to moderate complete membrane staining in &#x0003e;10% of the tumor cells; 3+: strong complete membrane staining observed in &#x0003e;10% of the tumor cells. ERBB2 protein expression was categorized as negative (scores 0 and 1+), or positive (scores 2+ and 3+) [<xref ref-type="bibr" rid="B29">29</xref>].</p></sec></sec><sec><title>Authors' contributions</title><p>SJC, TYW, and HWW designed the study project. SJC and TYW collected microarray data sets and EEC materials. SJC, TYW, CYT, and TFW executed project plan and data analysis. SJC, TYW, MDC, and HWW carried out data interpretation and discussion. SJC wrote the manuscript. Then HWW modified it. All authors read and approved the final manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>The discrimination ability of the 678 probe sets</bold>. Prediction power of the 678 probe sets differentiating early and late stage samples, as well as discriminating normal endometrium and tumor tissues.</p></caption><media xlink:href="1471-2164-10-613-S1.JPEG" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>The annotation of probed genes and cDNAs</bold>. Complete data of analyzed arrays and clustered genes/cDNAs.</p></caption><media xlink:href="1471-2164-10-613-S2.XLS" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>The authors acknowledge the efforts of IGC and expO. This work is supported by the Mackay Memorial Hospital (MMH-HB-97-05), the National Health Research Institute (NHRI-EX97-9704BI), the National Science Council (NSC97-3111-B-010-004 and NSC98-2320-B-010-020-MY3), Taipei Veterans General Hospital Research Fund, VGHUST Joint research Program, Tsou's Foundation (V98ER2-003), and Yang-Ming University (a grant from Ministry of Education, Aim for the Top University Plan).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Yilmaz</surname><given-names>OH</given-names></name><name><surname>Valdez</surname><given-names>R</given-names></name><name><surname>Theisen</surname><given-names>BK</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Ferguson</surname><given-names>DO</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name><article-title>Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells</article-title><source>Nature</source><year>2006</year><volume>441</volume><issue>7092</issue><fpage>475</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1038/nature04703</pub-id><pub-id pub-id-type="pmid">16598206</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Barnhart</surname><given-names>BC</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name><article-title>Metastasis and stem cell pathways</article-title><source>Cancer Metastasis Rev</source><year>2007</year><volume>26</volume><issue>2</issue><fpage>261</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1007/s10555-007-9053-3</pub-id><pub-id pub-id-type="pmid">17647111</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Trosko</surname><given-names>JE</given-names></name><article-title>Review paper: cancer stem cells and cancer nonstem cells: from adult stem cells or from reprogramming of differentiated somatic cells</article-title><source>Vet Pathol</source><year>2009</year><volume>46</volume><issue>2</issue><fpage>176</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">19261629</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Reya</surname><given-names>T</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><article-title>Stem cells, cancer, and cancer stem cells</article-title><source>Nature</source><year>2001</year><volume>414</volume><issue>6859</issue><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/35102167</pub-id><pub-id pub-id-type="pmid">11689955</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kotliarova</surname><given-names>S</given-names></name><name><surname>Kotliarov</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Su</surname><given-names>Q</given-names></name><name><surname>Donin</surname><given-names>NM</given-names></name><name><surname>Pastorino</surname><given-names>S</given-names></name><name><surname>Purow</surname><given-names>BW</given-names></name><name><surname>Christopher</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Park</surname><given-names>JK</given-names></name><name><surname>Fine</surname><given-names>HA</given-names></name><article-title>Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines</article-title><source>Cancer Cell</source><year>2006</year><volume>9</volume><issue>5</issue><fpage>391</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.03.030</pub-id><pub-id pub-id-type="pmid">16697959</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>ZJ</given-names></name><name><surname>Ellis</surname><given-names>T</given-names></name><name><surname>Markant</surname><given-names>SL</given-names></name><name><surname>Read</surname><given-names>TA</given-names></name><name><surname>Kessler</surname><given-names>JD</given-names></name><name><surname>Bourboulas</surname><given-names>M</given-names></name><name><surname>Schuller</surname><given-names>U</given-names></name><name><surname>Machold</surname><given-names>R</given-names></name><name><surname>Fishell</surname><given-names>G</given-names></name><name><surname>Rowitch</surname><given-names>DH</given-names></name><name><surname>Wainwright</surname><given-names>BJ</given-names></name><name><surname>Wechsler-Reya</surname><given-names>RJ</given-names></name><article-title>Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells</article-title><source>Cancer Cell</source><year>2008</year><volume>14</volume><issue>2</issue><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.07.003</pub-id><pub-id pub-id-type="pmid">18691548</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Schuller</surname><given-names>U</given-names></name><name><surname>Heine</surname><given-names>VM</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Kho</surname><given-names>AT</given-names></name><name><surname>Dillon</surname><given-names>AK</given-names></name><name><surname>Han</surname><given-names>YG</given-names></name><name><surname>Huillard</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Ligon</surname><given-names>AH</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Alvarez-Buylla</surname><given-names>A</given-names></name><name><surname>McMahon</surname><given-names>AP</given-names></name><name><surname>Rowitch</surname><given-names>DH</given-names></name><name><surname>Ligon</surname><given-names>KL</given-names></name><article-title>Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma</article-title><source>Cancer Cell</source><year>2008</year><volume>14</volume><issue>2</issue><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.07.005</pub-id><pub-id pub-id-type="pmid">18691547</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Perez-Caro</surname><given-names>M</given-names></name><name><surname>Cobaleda</surname><given-names>C</given-names></name><name><surname>Gonzalez-Herrero</surname><given-names>I</given-names></name><name><surname>Vicente-Duenas</surname><given-names>C</given-names></name><name><surname>Bermejo-Rodriguez</surname><given-names>C</given-names></name><name><surname>Sanchez-Beato</surname><given-names>M</given-names></name><name><surname>Orfao</surname><given-names>A</given-names></name><name><surname>Pintado</surname><given-names>B</given-names></name><name><surname>Flores</surname><given-names>T</given-names></name><name><surname>Sanchez-Martin</surname><given-names>M</given-names></name><name><surname>Jimenez</surname><given-names>R</given-names></name><name><surname>Piris</surname><given-names>MA</given-names></name><name><surname>Sanchez-Garcia</surname><given-names>I</given-names></name><article-title>Cancer induction by restriction of oncogene expression to the stem cell compartment</article-title><source>Embo J</source><year>2009</year><volume>28</volume><issue>1</issue><fpage>8</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/emboj.2008.253</pub-id><pub-id pub-id-type="pmid">19037256</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Counter</surname><given-names>CM</given-names></name><name><surname>Lundberg</surname><given-names>AS</given-names></name><name><surname>Beijersbergen</surname><given-names>RL</given-names></name><name><surname>Brooks</surname><given-names>MW</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name><article-title>Creation of human tumour cells with defined genetic elements</article-title><source>Nature</source><year>1999</year><volume>400</volume><issue>6743</issue><fpage>464</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1038/22780</pub-id><pub-id pub-id-type="pmid">10440377</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Kho</surname><given-names>AT</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Butte</surname><given-names>AJ</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Rowitch</surname><given-names>DH</given-names></name><name><surname>Kohane</surname><given-names>IS</given-names></name><article-title>Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers</article-title><source>Genes Dev</source><year>2004</year><volume>18</volume><issue>6</issue><fpage>629</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1101/gad.1182504</pub-id><pub-id pub-id-type="pmid">15075291</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Shivdasani</surname><given-names>RA</given-names></name><article-title>Overlapping gene expression in fetal mouse intestine development and human colorectal cancer</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><issue>19</issue><fpage>8715</fpage><lpage>8722</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0700</pub-id><pub-id pub-id-type="pmid">16204040</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Kaiser</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>YK</given-names></name><name><surname>Franklin</surname><given-names>JL</given-names></name><name><surname>Halberg</surname><given-names>RB</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Jessen</surname><given-names>WJ</given-names></name><name><surname>Freudenberg</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Haigis</surname><given-names>K</given-names></name><name><surname>Jegga</surname><given-names>AG</given-names></name><name><surname>Kong</surname><given-names>S</given-names></name><name><surname>Sakthivel</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Reichling</surname><given-names>T</given-names></name><name><surname>Azhar</surname><given-names>M</given-names></name><name><surname>Boivin</surname><given-names>GP</given-names></name><name><surname>Roberts</surname><given-names>RB</given-names></name><name><surname>Bissahoyo</surname><given-names>AC</given-names></name><name><surname>Gonzales</surname><given-names>F</given-names></name><name><surname>Bloom</surname><given-names>GC</given-names></name><name><surname>Eschrich</surname><given-names>S</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Aronow</surname><given-names>JE</given-names></name><name><surname>Kleimeyer</surname><given-names>J</given-names></name><name><surname>Kleimeyer</surname><given-names>M</given-names></name><name><surname>Ramaswamy</surname><given-names>V</given-names></name><name><surname>Settle</surname><given-names>SH</given-names></name><name><surname>Boone</surname><given-names>B</given-names></name><name><surname>Levy</surname><given-names>S</given-names></name><name><surname>Graff</surname><given-names>JM</given-names></name><article-title>Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer</article-title><source>Genome Biol</source><year>2007</year><volume>8</volume><issue>7</issue><fpage>R131</fpage><pub-id pub-id-type="doi">10.1186/gb-2007-8-7-r131</pub-id><pub-id pub-id-type="pmid">17615082</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Ben-Porath</surname><given-names>I</given-names></name><name><surname>Thomson</surname><given-names>MW</given-names></name><name><surname>Carey</surname><given-names>VJ</given-names></name><name><surname>Ge</surname><given-names>R</given-names></name><name><surname>Bell</surname><given-names>GW</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name><article-title>An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><issue>5</issue><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1038/ng.127</pub-id><pub-id pub-id-type="pmid">18443585</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Mani</surname><given-names>SA</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Liao</surname><given-names>MJ</given-names></name><name><surname>Eaton</surname><given-names>EN</given-names></name><name><surname>Ayyanan</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>AY</given-names></name><name><surname>Brooks</surname><given-names>M</given-names></name><name><surname>Reinhard</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>CC</given-names></name><name><surname>Shipitsin</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>LL</given-names></name><name><surname>Polyak</surname><given-names>K</given-names></name><name><surname>Brisken</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name><article-title>The epithelial-mesenchymal transition generates cells with properties of stem cells</article-title><source>Cell</source><year>2008</year><volume>133</volume><issue>4</issue><fpage>704</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.03.027</pub-id><pub-id pub-id-type="pmid">18485877</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Morel</surname><given-names>AP</given-names></name><name><surname>Lievre</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Hinkal</surname><given-names>G</given-names></name><name><surname>Ansieau</surname><given-names>S</given-names></name><name><surname>Puisieux</surname><given-names>A</given-names></name><article-title>Generation of breast cancer stem cells through epithelial-mesenchymal transition</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><issue>8</issue><fpage>e2888</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0002888</pub-id><pub-id pub-id-type="pmid">18682804</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>FS</given-names></name><article-title>Molecular carcinogenesis of endometrial cancer</article-title><source>Taiwan J Obstet Gynecol</source><year>2007</year><volume>46</volume><issue>1</issue><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/S1028-4559(08)60102-3</pub-id><pub-id pub-id-type="pmid">17389185</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Sorosky</surname><given-names>JI</given-names></name><article-title>Endometrial cancer</article-title><source>Obstet Gynecol</source><year>2008</year><volume>111</volume><issue>2 Pt 1</issue><fpage>436</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">18238985</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>Ridgway</surname><given-names>RA</given-names></name><name><surname>van Es</surname><given-names>JH</given-names></name><name><surname>Wetering</surname><given-names>M van de</given-names></name><name><surname>Begthel</surname><given-names>H</given-names></name><name><surname>Born</surname><given-names>M van den</given-names></name><name><surname>Danenberg</surname><given-names>E</given-names></name><name><surname>Clarke</surname><given-names>AR</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><article-title>Crypt stem cells as the cells-of-origin of intestinal cancer</article-title><source>Nature</source><year>2009</year><volume>457</volume><issue>7229</issue><fpage>608</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1038/nature07602</pub-id><pub-id pub-id-type="pmid">19092804</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Gibson</surname><given-names>P</given-names></name><name><surname>Currle</surname><given-names>DS</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Richardson</surname><given-names>RJ</given-names></name><name><surname>Bayazitov</surname><given-names>IT</given-names></name><name><surname>Poppleton</surname><given-names>H</given-names></name><name><surname>Zakharenko</surname><given-names>S</given-names></name><name><surname>Ellison</surname><given-names>DW</given-names></name><name><surname>Gilbertson</surname><given-names>RJ</given-names></name><article-title>Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation</article-title><source>Nature</source><year>2009</year><volume>457</volume><issue>7229</issue><fpage>603</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1038/nature07589</pub-id><pub-id pub-id-type="pmid">19092805</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Flier</surname><given-names>LG van der</given-names></name><name><surname>Haegebarth</surname><given-names>A</given-names></name><name><surname>Stange</surname><given-names>DE</given-names></name><name><surname>Wetering</surname><given-names>M van de</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><article-title>OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells</article-title><source>Gastroenterology</source><year>2009</year><volume>137</volume><issue>1</issue><fpage>15</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.05.035</pub-id><pub-id pub-id-type="pmid">19450592</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>HW</given-names></name><name><surname>Trotter</surname><given-names>MW</given-names></name><name><surname>Lagos</surname><given-names>D</given-names></name><name><surname>Bourboulia</surname><given-names>D</given-names></name><name><surname>Henderson</surname><given-names>S</given-names></name><name><surname>Makinen</surname><given-names>T</given-names></name><name><surname>Elliman</surname><given-names>S</given-names></name><name><surname>Flanagan</surname><given-names>AM</given-names></name><name><surname>Alitalo</surname><given-names>K</given-names></name><name><surname>Boshoff</surname><given-names>C</given-names></name><article-title>Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma</article-title><source>Nat Genet</source><year>2004</year><volume>36</volume><issue>7</issue><fpage>687</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1038/ng1384</pub-id><pub-id pub-id-type="pmid">15220918</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>TS</given-names></name><name><surname>Hsieh</surname><given-names>JY</given-names></name><name><surname>Wu</surname><given-names>YH</given-names></name><name><surname>Jen</surname><given-names>CH</given-names></name><name><surname>Tsuang</surname><given-names>YH</given-names></name><name><surname>Chiou</surname><given-names>SH</given-names></name><name><surname>Partanen</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>H</given-names></name><name><surname>Jaatinen</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>HW</given-names></name><article-title>Functional network reconstruction reveals somatic stemness genetic maps and dedifferentiation-like transcriptome reprogramming induced by GATA2</article-title><source>Stem Cells</source><year>2008</year><volume>26</volume><issue>5</issue><fpage>1186</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1634/stemcells.2007-0821</pub-id><pub-id pub-id-type="pmid">18308945</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Slonim</surname><given-names>DK</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Huard</surname><given-names>C</given-names></name><name><surname>Gaasenbeek</surname><given-names>M</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Coller</surname><given-names>H</given-names></name><name><surname>Loh</surname><given-names>ML</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Caligiuri</surname><given-names>MA</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><article-title>Molecular classification of cancer: class discovery and class prediction by gene expression monitoring</article-title><source>Science</source><year>1999</year><volume>286</volume><issue>5439</issue><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1126/science.286.5439.531</pub-id><pub-id pub-id-type="pmid">10521349</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>KN</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><article-title>A molecular signature of metastasis in primary solid tumors</article-title><source>Nat Genet</source><year>2003</year><volume>33</volume><issue>1</issue><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/ng1060</pub-id><pub-id pub-id-type="pmid">12469122</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Jen</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>TP</given-names></name><name><surname>Tung</surname><given-names>CY</given-names></name><name><surname>Su</surname><given-names>SH</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Hsu</surname><given-names>MT</given-names></name><name><surname>Wang</surname><given-names>HW</given-names></name><article-title>Signature Evaluation Tool (SET): a Java-based tool to evaluate and visualize the sample discrimination abilities of gene expression signatures</article-title><source>BMC Bioinformatics</source><year>2008</year><volume>9</volume><issue>1</issue><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-9-58</pub-id><pub-id pub-id-type="pmid">18221568</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Shabo</surname><given-names>I</given-names></name><name><surname>Stal</surname><given-names>O</given-names></name><name><surname>Olsson</surname><given-names>H</given-names></name><name><surname>Dore</surname><given-names>S</given-names></name><name><surname>Svanvik</surname><given-names>J</given-names></name><article-title>Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival</article-title><source>Int J Cancer</source><year>2008</year><volume>123</volume><issue>4</issue><fpage>780</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1002/ijc.23527</pub-id><pub-id pub-id-type="pmid">18506688</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Komohara</surname><given-names>Y</given-names></name><name><surname>Ohnishi</surname><given-names>K</given-names></name><name><surname>Kuratsu</surname><given-names>J</given-names></name><name><surname>Takeya</surname><given-names>M</given-names></name><article-title>Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas</article-title><source>J Pathol</source><year>2008</year><volume>216</volume><issue>1</issue><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1002/path.2370</pub-id><pub-id pub-id-type="pmid">18553315</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Uharcek</surname><given-names>P</given-names></name><article-title>Prognostic factors in endometrial carcinoma</article-title><source>J Obstet Gynaecol Res</source><year>2008</year><volume>34</volume><issue>5</issue><fpage>776</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1111/j.1447-0756.2008.00796.x</pub-id><pub-id pub-id-type="pmid">18958927</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Grushko</surname><given-names>TA</given-names></name><name><surname>Filiaci</surname><given-names>VL</given-names></name><name><surname>Mundt</surname><given-names>AJ</given-names></name><name><surname>Ridderstrale</surname><given-names>K</given-names></name><name><surname>Olopade</surname><given-names>OI</given-names></name><name><surname>Fleming</surname><given-names>GF</given-names></name><article-title>An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study</article-title><source>Gynecol Oncol</source><year>2008</year><volume>108</volume><issue>1</issue><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2007.09.007</pub-id><pub-id pub-id-type="pmid">17945336</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Strojan</surname><given-names>P</given-names></name><name><surname>Budihna</surname><given-names>M</given-names></name><name><surname>Smid</surname><given-names>L</given-names></name><name><surname>Svetic</surname><given-names>B</given-names></name><name><surname>Vrhovec</surname><given-names>I</given-names></name><name><surname>Kos</surname><given-names>J</given-names></name><name><surname>Skrk</surname><given-names>J</given-names></name><article-title>Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><issue>3</issue><fpage>1052</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">10741734</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Byers</surname><given-names>RJ</given-names></name><name><surname>Sakhinia</surname><given-names>E</given-names></name><name><surname>Joseph</surname><given-names>P</given-names></name><name><surname>Glennie</surname><given-names>C</given-names></name><name><surname>Hoyland</surname><given-names>JA</given-names></name><name><surname>Menasce</surname><given-names>LP</given-names></name><name><surname>Radford</surname><given-names>JA</given-names></name><name><surname>Illidge</surname><given-names>T</given-names></name><article-title>Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling</article-title><source>Blood</source><year>2008</year><volume>111</volume><issue>9</issue><fpage>4764</fpage><lpage>4770</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-10-115915</pub-id><pub-id pub-id-type="pmid">18174380</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Salvesen</surname><given-names>HB</given-names></name><name><surname>Akslen</surname><given-names>LA</given-names></name><article-title>Molecular pathogenesis and prognostic factors in endometrial carcinoma</article-title><source>APMIS</source><year>2002</year><volume>110</volume><issue>10</issue><fpage>673</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0463.2002.1101001.x</pub-id><pub-id pub-id-type="pmid">12583434</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>An</surname><given-names>C</given-names></name><name><surname>Choi</surname><given-names>IS</given-names></name><name><surname>Yao</surname><given-names>JC</given-names></name><name><surname>Worah</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>K</given-names></name><name><surname>Mansfield</surname><given-names>PF</given-names></name><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Rashid</surname><given-names>A</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><name><surname>Wu</surname><given-names>TT</given-names></name><article-title>Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><issue>2 Pt 1</issue><fpage>656</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">15701853</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Toyota</surname><given-names>M</given-names></name><name><surname>Kopecky</surname><given-names>KJ</given-names></name><name><surname>Toyota</surname><given-names>MO</given-names></name><name><surname>Jair</surname><given-names>KW</given-names></name><name><surname>Willman</surname><given-names>CL</given-names></name><name><surname>Issa</surname><given-names>JP</given-names></name><article-title>Methylation profiling in acute myeloid leukemia</article-title><source>Blood</source><year>2001</year><volume>97</volume><issue>9</issue><fpage>2823</fpage><lpage>2829</lpage><pub-id pub-id-type="doi">10.1182/blood.V97.9.2823</pub-id><pub-id pub-id-type="pmid">11313277</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Bieche</surname><given-names>I</given-names></name><name><surname>Lerebours</surname><given-names>F</given-names></name><name><surname>Tozlu</surname><given-names>S</given-names></name><name><surname>Espie</surname><given-names>M</given-names></name><name><surname>Marty</surname><given-names>M</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name><article-title>Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><issue>20</issue><fpage>6789</fpage><lpage>6795</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0306</pub-id><pub-id pub-id-type="pmid">15501955</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Skibbens</surname><given-names>RV</given-names></name><article-title>Cell biology of cancer: BRCA1 and sister chromatid pairing reactions?</article-title><source>Cell Cycle</source><year>2008</year><volume>7</volume><issue>4</issue><fpage>449</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">18235242</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Juric</surname><given-names>D</given-names></name><name><surname>Sale</surname><given-names>S</given-names></name><name><surname>Hromas</surname><given-names>RA</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Duran</surname><given-names>GE</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Einhorn</surname><given-names>LH</given-names></name><name><surname>Sikic</surname><given-names>BI</given-names></name><article-title>Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><issue>49</issue><fpage>17763</fpage><lpage>17768</lpage><pub-id pub-id-type="doi">10.1073/pnas.0509082102</pub-id><pub-id pub-id-type="pmid">16306258</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Kho</surname><given-names>DH</given-names></name><name><surname>Bae</surname><given-names>JA</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name><name><surname>Seo</surname><given-names>YW</given-names></name><name><surname>Ahn</surname><given-names>KY</given-names></name><name><surname>Chung</surname><given-names>IJ</given-names></name><name><surname>Kim</surname><given-names>KK</given-names></name><article-title>KITENIN recruits Dishevelled/PKC delta to form a functional complex and controls the migration and invasiveness of colorectal cancer cells</article-title><source>Gut</source><year>2009</year><volume>58</volume><issue>4</issue><fpage>509</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1136/gut.2008.150938</pub-id><pub-id pub-id-type="pmid">18653728</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Birnie</surname><given-names>R</given-names></name><name><surname>Bryce</surname><given-names>SD</given-names></name><name><surname>Roome</surname><given-names>C</given-names></name><name><surname>Dussupt</surname><given-names>V</given-names></name><name><surname>Droop</surname><given-names>A</given-names></name><name><surname>Lang</surname><given-names>SH</given-names></name><name><surname>Berry</surname><given-names>PA</given-names></name><name><surname>Hyde</surname><given-names>CF</given-names></name><name><surname>Lewis</surname><given-names>JL</given-names></name><name><surname>Stower</surname><given-names>MJ</given-names></name><name><surname>Maitland</surname><given-names>NJ</given-names></name><name><surname>Collins</surname><given-names>AT</given-names></name><article-title>Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions</article-title><source>Genome Biol</source><year>2008</year><volume>9</volume><issue>5</issue><fpage>R83</fpage><pub-id pub-id-type="doi">10.1186/gb-2008-9-5-r83</pub-id><pub-id pub-id-type="pmid">18492237</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Arribas</surname><given-names>J</given-names></name><name><surname>Esselens</surname><given-names>C</given-names></name><article-title>ADAM17 as a therapeutic target in multiple diseases</article-title><source>Curr Pharm Des</source><year>2009</year><volume>15</volume><issue>20</issue><fpage>2319</fpage><lpage>2335</lpage><pub-id pub-id-type="doi">10.2174/138161209788682398</pub-id><pub-id pub-id-type="pmid">19601834</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Yamazaki</surname><given-names>K</given-names></name><name><surname>Takamura</surname><given-names>M</given-names></name><name><surname>Masugi</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Hibi</surname><given-names>T</given-names></name><name><surname>Hiraoka</surname><given-names>N</given-names></name><name><surname>Ohta</surname><given-names>T</given-names></name><name><surname>Ohki</surname><given-names>M</given-names></name><name><surname>Hirohashi</surname><given-names>S</given-names></name><name><surname>Sakamoto</surname><given-names>M</given-names></name><article-title>Adenylate cyclase-associated protein 1 overexpressed in pancreatic cancers is involved in cancer cell motility</article-title><source>Lab Invest</source><year>2009</year><volume>89</volume><issue>4</issue><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2009.5</pub-id><pub-id pub-id-type="pmid">19188911</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Thompson</surname><given-names>CC</given-names></name><name><surname>Ashcroft</surname><given-names>FJ</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Saraga</surname><given-names>G</given-names></name><name><surname>Vimalachandran</surname><given-names>D</given-names></name><name><surname>Prime</surname><given-names>W</given-names></name><name><surname>Campbell</surname><given-names>F</given-names></name><name><surname>Dodson</surname><given-names>A</given-names></name><name><surname>Jenkins</surname><given-names>RE</given-names></name><name><surname>Lemoine</surname><given-names>NR</given-names></name><name><surname>Crnogorac-Jurcevic</surname><given-names>T</given-names></name><name><surname>Yin</surname><given-names>HL</given-names></name><name><surname>Costello</surname><given-names>E</given-names></name><article-title>Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility</article-title><source>Gut</source><year>2007</year><volume>56</volume><issue>1</issue><fpage>95</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1136/gut.2005.083691</pub-id><pub-id pub-id-type="pmid">16847067</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Labauge</surname><given-names>P</given-names></name><name><surname>Denier</surname><given-names>C</given-names></name><name><surname>Bergametti</surname><given-names>F</given-names></name><name><surname>Tournier-Lasserve</surname><given-names>E</given-names></name><article-title>Genetics of cavernous angiomas</article-title><source>Lancet Neurol</source><year>2007</year><volume>6</volume><issue>3</issue><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(07)70053-4</pub-id><pub-id pub-id-type="pmid">17303530</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Shan</surname><given-names>J</given-names></name><name><surname>Long</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><article-title>PDCD10 interacts with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway</article-title><source>Mol Biol Cell</source><year>2007</year><volume>18</volume><issue>6</issue><fpage>1965</fpage><lpage>1978</lpage><pub-id pub-id-type="doi">10.1091/mbc.E06-07-0608</pub-id><pub-id pub-id-type="pmid">17360971</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Lemon</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>PY</given-names></name><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Morrison</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Szoke</surname><given-names>J</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name><name><surname>Watson</surname><given-names>M</given-names></name><name><surname>Govindan</surname><given-names>R</given-names></name><name><surname>You</surname><given-names>M</given-names></name><article-title>A gene expression signature predicts survival of patients with stage I non-small cell lung cancer</article-title><source>PLoS Med</source><year>2006</year><volume>3</volume><issue>12</issue><fpage>e467</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0030467</pub-id><pub-id pub-id-type="pmid">17194181</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Chiu</surname><given-names>SY</given-names></name><name><surname>Asai</surname><given-names>N</given-names></name><name><surname>Costantini</surname><given-names>F</given-names></name><name><surname>Hsu</surname><given-names>W</given-names></name><article-title>SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages</article-title><source>PLoS Biol</source><year>2008</year><volume>6</volume><issue>12</issue><fpage>e310</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.0060310</pub-id><pub-id pub-id-type="pmid">19090619</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Hoffman</surname><given-names>AE</given-names></name><name><surname>Zheng</surname><given-names>T</given-names></name><name><surname>Ba</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><article-title>The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response</article-title><source>Mol Cancer Res</source><year>2008</year><volume>6</volume><issue>9</issue><fpage>1461</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-07-2094</pub-id><pub-id pub-id-type="pmid">18819933</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Deshpande</surname><given-names>AM</given-names></name><name><surname>Akunowicz</surname><given-names>JD</given-names></name><name><surname>Reveles</surname><given-names>XT</given-names></name><name><surname>Patel</surname><given-names>BB</given-names></name><name><surname>Saria</surname><given-names>EA</given-names></name><name><surname>Gorlick</surname><given-names>RG</given-names></name><name><surname>Naylor</surname><given-names>SL</given-names></name><name><surname>Leach</surname><given-names>RJ</given-names></name><name><surname>Hansen</surname><given-names>MF</given-names></name><article-title>PHC3, a component of the hPRC-H complex, associates with E2F6 during G0 and is lost in osteosarcoma tumors</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><issue>12</issue><fpage>1714</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209988</pub-id><pub-id pub-id-type="pmid">17001316</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Yu</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Chang</surname><given-names>GC</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Yuan</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>CL</given-names></name><name><surname>Wang</surname><given-names>CH</given-names></name><name><surname>Terng</surname><given-names>HJ</given-names></name><name><surname>Kao</surname><given-names>SF</given-names></name><name><surname>Chan</surname><given-names>WK</given-names></name><name><surname>Li</surname><given-names>HN</given-names></name><name><surname>Liu</surname><given-names>CC</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>WJ</given-names></name><name><surname>Chen</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>PC</given-names></name><article-title>A five-gene signature and clinical outcome in non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><issue>1</issue><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa060096</pub-id><pub-id pub-id-type="pmid">17202451</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Chang</surname><given-names>GC</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>CL</given-names></name><name><surname>Yu</surname><given-names>CJ</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>HS</given-names></name><name><surname>Su</surname><given-names>TJ</given-names></name><name><surname>Chiang</surname><given-names>CC</given-names></name><name><surname>Li</surname><given-names>HN</given-names></name><name><surname>Hong</surname><given-names>QS</given-names></name><name><surname>Su</surname><given-names>HY</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>WJ</given-names></name><name><surname>Liu</surname><given-names>CC</given-names></name><name><surname>Chan</surname><given-names>WK</given-names></name><name><surname>Li</surname><given-names>KC</given-names></name><name><surname>Chen</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>PC</given-names></name><article-title>MicroRNA signature predicts survival and relapse in lung cancer</article-title><source>Cancer Cell</source><year>2008</year><volume>13</volume><issue>1</issue><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2007.12.008</pub-id><pub-id pub-id-type="pmid">18167339</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Weigelt</surname><given-names>B</given-names></name><name><surname>Glas</surname><given-names>AM</given-names></name><name><surname>Wessels</surname><given-names>LF</given-names></name><name><surname>Witteveen</surname><given-names>AT</given-names></name><name><surname>Peterse</surname><given-names>JL</given-names></name><name><surname>van't Veer</surname><given-names>LJ</given-names></name><article-title>Gene expression profiles of primary breast tumors maintained in distant metastases</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><issue>26</issue><fpage>15901</fpage><lpage>15905</lpage><pub-id pub-id-type="doi">10.1073/pnas.2634067100</pub-id><pub-id pub-id-type="pmid">14665696</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Podsypanina</surname><given-names>K</given-names></name><name><surname>Du</surname><given-names>YC</given-names></name><name><surname>Jechlinger</surname><given-names>M</given-names></name><name><surname>Beverly</surname><given-names>LJ</given-names></name><name><surname>Hambardzumyan</surname><given-names>D</given-names></name><name><surname>Varmus</surname><given-names>H</given-names></name><article-title>Seeding and propagation of untransformed mouse mammary cells in the lung</article-title><source>Science</source><year>2008</year><volume>321</volume><issue>5897</issue><fpage>1841</fpage><lpage>1844</lpage><pub-id pub-id-type="doi">10.1126/science.1161621</pub-id><pub-id pub-id-type="pmid">18755941</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Husemann</surname><given-names>Y</given-names></name><name><surname>Geigl</surname><given-names>JB</given-names></name><name><surname>Schubert</surname><given-names>F</given-names></name><name><surname>Musiani</surname><given-names>P</given-names></name><name><surname>Meyer</surname><given-names>M</given-names></name><name><surname>Burghart</surname><given-names>E</given-names></name><name><surname>Forni</surname><given-names>G</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Fehm</surname><given-names>T</given-names></name><name><surname>Riethmuller</surname><given-names>G</given-names></name><name><surname>Klein</surname><given-names>CA</given-names></name><article-title>Systemic spread is an early step in breast cancer</article-title><source>Cancer Cell</source><year>2008</year><volume>13</volume><issue>1</issue><fpage>58</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2007.12.003</pub-id><pub-id pub-id-type="pmid">18167340</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>SJ</given-names></name><name><surname>Huang</surname><given-names>TS</given-names></name><name><surname>Wang</surname><given-names>KL</given-names></name><name><surname>Wang</surname><given-names>TY</given-names></name><name><surname>Yang</surname><given-names>YC</given-names></name><name><surname>Chang</surname><given-names>MD</given-names></name><name><surname>Wu</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>HW</given-names></name><article-title>Genetic network analysis of human CD34+ hematopoietic stem/precursor cells</article-title><source>Taiwanese Journal of Obstetrics &#x00026; Gynecology</source><year>2008</year><volume>47</volume><issue>4</issue><fpage>422</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/S1028-4559(09)60010-3</pub-id><pub-id pub-id-type="pmid">19126509</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>TP</given-names></name><name><surname>Chang</surname><given-names>TY</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Hsu</surname><given-names>MT</given-names></name><name><surname>Wang</surname><given-names>HW</given-names></name><article-title>ArrayFusion: a web application for multi-dimensional analysis of CGH, SNP and microarray data</article-title><source>Bioinformatics</source><year>2006</year><volume>22</volume><issue>21</issue><fpage>2697</fpage><lpage>2698</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btl457</pub-id><pub-id pub-id-type="pmid">16935928</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="other"><name><surname>Harris</surname><given-names>MA</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Ireland</surname><given-names>A</given-names></name><name><surname>Lomax</surname><given-names>J</given-names></name><name><surname>Ashburner</surname><given-names>M</given-names></name><name><surname>Foulger</surname><given-names>R</given-names></name><name><surname>Eilbeck</surname><given-names>K</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Marshall</surname><given-names>B</given-names></name><name><surname>Mungall</surname><given-names>C</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Rubin</surname><given-names>GM</given-names></name><name><surname>Blake</surname><given-names>JA</given-names></name><name><surname>Bult</surname><given-names>C</given-names></name><name><surname>Dolan</surname><given-names>M</given-names></name><name><surname>Drabkin</surname><given-names>H</given-names></name><name><surname>Eppig</surname><given-names>JT</given-names></name><name><surname>Hill</surname><given-names>DP</given-names></name><name><surname>Ni</surname><given-names>L</given-names></name><name><surname>Ringwald</surname><given-names>M</given-names></name><name><surname>Balakrishnan</surname><given-names>R</given-names></name><name><surname>Cherry</surname><given-names>JM</given-names></name><name><surname>Christie</surname><given-names>KR</given-names></name><name><surname>Costanzo</surname><given-names>MC</given-names></name><name><surname>Dwight</surname><given-names>SS</given-names></name><name><surname>Engel</surname><given-names>S</given-names></name><name><surname>Fisk</surname><given-names>DG</given-names></name><name><surname>Hirschman</surname><given-names>JE</given-names></name><name><surname>Hong</surname><given-names>EL</given-names></name><name><surname>Nash</surname><given-names>RS</given-names></name><article-title>The Gene Ontology (GO) database and informatics resource</article-title><source>Nucleic Acids Res</source><year>2004</year><issue>32 Database</issue><fpage>D258</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">14681407</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Dennis</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Hosack</surname><given-names>DA</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name><article-title>DAVID: Database for Annotation, Visualization, and Integrated Discovery</article-title><source>Genome Biol</source><year>2003</year><volume>4</volume><issue>5</issue><fpage>P3</fpage><pub-id pub-id-type="doi">10.1186/gb-2003-4-5-p3</pub-id><pub-id pub-id-type="pmid">12734009</pub-id></mixed-citation></ref></ref-list></back></article>